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11. INTRODUCTION
1.1.The major histocompatibility complex (MHC)
The major histocompatibility complex (MHC) is a group of genes, coding for a set
of host cell surface molecules that bind to peptide fragments derived from pathogens and
display them on the host cell surface for recognition by the appropriate T-cells. MHC coded
proteins are also called as human leukocyte antigens (HLA) as it was first discovered on the
surface of leukocytes in humans.
There are three regions in MHC, they are region I and region II, region III. Each
region code for specific proteins called HLA class I molecules and HLA class II molecules by
region I and region II of MHC respectively. Region III codes for complement factors (C2, C4,
C3 convertase, factor B and properdin), heat shock protein (HSP) and tumor necrosis factor
(TNFα, and β) and steroid 21-hydroxylases.(1)
1.1.1. MHC class 1 molecules
MHC-class1 proteins are located on the surface of all nucleated cells (except
sperm cells) and platelets. They are absent in RBCs. They present the peptide antigen to CD8
cells.
1.1.2. Structure and Function of HLA
Major histocompatibility complex (MHC) class I molecules are heterodimeric
complexes consisting of a heavy chain (HC), β2-microglobulin (β2m or light chain), and a
peptide (commonly 8-11amino acids in length) that are located on the surface of most
nucleated cells. Their function is to present peptides to a variety of ligands, in particular T cell
receptors (TCR), residing on the surface of cytotoxic T cells (CTL) (2).
HLA plays an important role in immune responses such as antigen presentation and
recognition of self peptides and non-self peptides as these responses affect the T cell receptors
2and coordination of cellular and humoral immunity. These antigens are the inherited gene
markers(1).
1.2. HLA and disease susceptibility
Some HLA alleles occur at a much higher frequency in those suffering from certain
diseases than in the general population. The diseases associated with particular MHC alleles
include autoimmune disorders, certain viral diseases, disorders of the complement system,
some neurologic disorders, and several different allergies.
One of the strongest known linkages between the presence of HLA allele and disease
susceptibility is that HLA-B27 to inflammatory Spondyloarthropathy,  that was first recognized
in 1973. (3, 4)
Benjamin and Parham have suggested that HLA B27 in some individuals might
predispose to Spondyloarthritis by binding one or more specific ‘arthritogenic’ peptides and
stimulating arthritogenic T cells.( 5,6)
There are many subtypes in HLA B27, the identification of different molecular
subtypes of HLA B27, which differ in the amino acid composition of their peptide binding
groove has led to studies of the disease association with different subtypes (7).
1.3.Spondyloarthropathy (SpA)
Spondyloarthropathy (SpA)s are multifactorial diseases that constitute a cluster of
interrelated overlapping chronic inflammatory diseases, such as reactive arthritis (ReA),
psoriatic arthritis (PsA), enteropathic arthritis, a subgroup of juvenile chronic arthritis,
ankylosing spondylitis (AS), and undifferentiated Spondyloarthropathy (USpA). They seem to
have an immune-mediated pathogenesis that share a number of clinical, radiographic, and
genetic characteristics with a well-defined group of rheumatic disorders.(8)
Association of HLA-B27 with the entire group of Spondyloarthropathy is well known and its
3association varies markedly among different forms of SpA and among different ethnic
populations.(9)
Prevalence of SpA worldwide varies from 0.1% to1.4% in general population
depending on the geographical region studied.(10) Despite the fact that SpA tends to affect
males more frequently and severely than it does females, an increasing proportion of female
patients has being observed during the last decade among patients with less severe clinical
manifestations.(11)
Predominantly, SpA begins in individuals younger than 45 years of age and
clinically compromises the axial spine, peripheral joints, tendons and ligament insertions
(entheses), and also has extra musculoskeletal manifestations in the skin, mucosa, gut and the
eyes.(12)
However there are other factors that have an impact on the onset of the disease,
such as environmental factors, and other genetic factors, including those within the major
histocompatibility complex (MHC) class I HLA B60/HLA-B40, HLA-B39, HLA-B14, and
HLA-B15and class II DRB1-alleles.(13)
1.4. Prevalence of HLA B27 in Spondyloarthropathy:
It has been estimated that HLA B27 allele is responsible for up to 28% of the
aetiology of SpA.(14)However, the prevalence of HLA-B27 varies among populations and
ethnic groups worldwide. For example, about 8% of Caucasians, 4% of North Africans, 2-9%
of Chinese and  0.1-0.5% of Japanese descent possess this gene.(15) Molecular studies have
revealed at least 31 HLA-B27 subtypes with various distributions in different
populations(16).These subtypes differ by one or more amino acid substitutions in the antigenic
peptide-binding groove(17).
1.5. Diseases associated with HLA B27
 Ankylosing spondylitis(AS)
4 Reactive arthritis (follows infection with species of Chlamydia, Campylobacter,
Salmonella, Shigella and Yersinia)
 Sacroiliitis associated with psoriasis
 Sacroiliitis associated with inflammatory bowel disease
 Undifferentiated oligoarthropathy
 Anterior uveitis
 Aortic regurgitation together with cardiac conduction abnormality
 Entheses-related juvenile idiopathic arthritis (18)
1.6. Diagnosis
The diagnosis of SpA is made principally based on clinical, radiological and
laboratory findings. In the laboratory it can be diagnosed by nonspecific tests like ESR,CRP
and a specific test like HLAB27 detection.
There are 3 methods available for detection of HLAB27. These are 1.Microlymphocytotoxicity
(MLCT) 2.Flowcytometry 3.Polymerase chain reaction (PCR).Of which PCR is the ” gold
standard method” method with sensitivity of 100% and specificity of 100%.
HLA B27 detection limits the diagnosis to SpA by excluding rheumatoid arthritis and
other connective tissue disorders .In most adult patients, Ankylosing spondylitis can be
diagnosed clinically without the HLA-B27 test. This assessment has no additional value in
established disease or as a pure screening tool (19).
However, in young patients with inflammatory chronic back pain, a positive HLA B27
test increases the likelihood of having AS, particularly if imaging of the sacroiliac (SI) joints
does not provide conclusive results. So HLA typing is helpful in early diagnosis of SpA and for
early diagnosis of other manifestations associated with it and institution of early therapy with
Disease-modifying anti rheumatic drugs (DMARDS) and Biologics. HLA B27 detection is also
used as a prognostic factor in the management of SPA.
5Therefore, the aim of this study was to investigate the frequency of HLA-B27 antigen among
suspected SpA patients as well as healthy people by PCR.
62. AIM AND OBJECTIVES
 To detect the frequency of HLA B27 Antigen among Seronegative Spondyloarthropthy
patients by PCR .
 To assess the frequency of HLA B27 Antigen in normal population.
 To determine the association of HLA B27 in various manifestations of Seronegative
Spondyloarthropathy.
 To correlate ESR, CRP, with HLA B27 among Spondyloarthropathy patients.
 To compare the sensitivity of X-Ray, MRI, ESR,CRP and HLAB27 detection in early
diagnosis of Seronegative Spondyloarthropathy
73.REVIEW OF LITRATURE
3.1.The Major Histocompatibility Complex
The major histocompatibility complex is a group which contains many genes
arranged within a long continuous stretch of DNA on chromosome 6 in humans and on
chromosome 17 in mice. The MHC is referred to as the HLA(Human Leucocyte Antigen)
complex in humans and as the H-2 complex in mice. Arrangement of genes is somewhat
different, in both cases the MHC genes are organized into many regions encoding three classes
of molecule called MHC molecules or HLA(Human Leucocyte Antigen) (1).
3.1.1.MHC Genes and Molecules
The HLA linked genes are subdivided into three groups: class I, class II and class III,
which are structurally and functionally distinct.
 Class I MHC genes - In  humans Class I MHC molecules encoded  by the A, B, and C
loci were the first discovered, and they are expressed in the widest range of cell types.
These are referred  as classical class I molecules. Additional genes or groups of genes
within  HLA complexes in humans also encode class I molecules; these genes are referred
as nonclassical class I genes.
MHC class Ι genes Encode glycoproteins that are expressed on the surface of nearly
all nucleated cells. These class I MHC molecules are membrane-bound glycoproteins that function
as specialized antigen-presenting molecules that form unusually stable complexes with antigenic
peptides and displaying them on the cell surface for recognition by cytotoxic T
lymphocytes(CTL).(1)
 Class II MHC genes encode glycoproteins  that are expressed primarily on antigen-
presenting cells ( eg:macrophages,dendritic cells, and also B cells), where they present
processed antigenic peptides to Helper T lymphocytes .
8 Class III MHC genes encode the complement components C4, Bf and C2 the gcnes for
the C21-hydroxylase.C2 and C4 complement factors are important in the classical
pathway, while Bf is the proactivator of C3 in the alternate pathway of complement
activation. Their immunological importance is best documented by the observation of
severe lupus like syndromes in the rare cases of genetic deficiency of C2 or C4 (20).
The human HLA complex is highly polymorphic and multiple alleles of each class I
and class II gene exist. However, the human MHC loci are closely linked and usually inherited
as a haplotype. When the father and mother have different haplotypes, there is a one-in-four
chance that siblings will inherit the same paternal and maternal haplotypes and therefore be
histocompatible with each other; none of the offspring will be histocompatible with the parents
3.2.Structure and function of HLA
Class I MHC molecules made up of two different glycoprotein chains which contain a 45-
kilodalton (kDa) α chain associated noncovalently with a 12- kDa β2-microglobulin
molecule.
3.2.1.α chain
The α chain is a transmembrane glycoprotein which is encoded by polymorphic genes within
the A, B, and C regions of the human HLA complex. The α chain is anchored in the plasma
membrane by its hydrophobic transmembrane segment and hydrophilic cytoplasmic tail.
Structural analyses have revealed that the α chain of class I MHC molecules have
 Three external domains named as α1, α2, and α3, each of which containing
approximately 90 amino acids;
 A transmembrane domain of about 25 hydrophobic amino acids followed by
9 A short stretch of charged amino acids , these are hydrophilic in nature; and
 A cytoplasmic anchor segment of 30 amino acids.
3.2.2. β2 Microglobulin
β2 Microglobulin is a protein encoded by a gene located on a different chromosome
which is highly conserved. The β2-microglobulin is similar in size and organization to the α3
domain; it does not contain a transmembrane region and also it is noncovalently bound to the
class I glycoprotein.
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Association of the α chain with β2-microglobulin is necessary for expression of class
I molecules on cell membranes. In Daudi cells (a type of human B cell tumor cell which are
not able to produce β2 microglobulin), it is observed that they synthesize MHC-1 molecules
but do not express them on cell surface.
The α3 domain appears to be highly conserved among class I MHC molecules and contains a
sequence that interacts with the CD8 membrane molecule present on cytotoxic T cells.
3.2.3.Function of HLA
The class I genes in HLA-A, Band C loci code for the classical transplantation
antigens expressed on the surface of all nucleated cells,These class I antigens are recognised in
association with antigen by the T -cell receptor of cytotoxicT-lymphocytes, therefore they form
the target for self-recognition.
The action of cytotoxic T -cells against autologous cells which are either infected or
show malignant transformation or which are chemically modulated, is considered to be one of
the most important functions of immunological surveillance (21).
Both class I and class II MHC-encoded molecules have distinct but related,
functional requirements in immune recognition. The class I molecules primarily bind with
antigenic peptides available to them in their biosynthetic journey from the rough endoplasmic
reticulum to the plasma membrane, while class II molecules bind proteolytic fragments derived
from endocytosed extracellular proteins generated in acidic cellular compartments (22).
This functional distinction between these molecules can be further illustrated by the
mutually exclusive expression of mature T -cells that are committed to the class I -and class ΙΙ -
peptide complexes respectively (23).
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3.3.MHC and Disease Susceptibility
Some HLA alleles occur at a much higher frequency in those suffering from certain
diseases than  in general population.The diseases associated with particular MHC alleles
include autoimmune disorders,certain viral diseases,disorders of the complement system,some
neurologic disorders and several allergies.
Certain class I or class II genotypes may provide a defect in the T -cell repertoire, which could
lead to the type of autoimmunity seen in HLA-associated diseases (24). The class II site is
associated with subsets of RA.
One of such association is HLA B27 and spondyloarthropathy.HLA-B27 is an allele of
the HLA-B locus of the human leukocyte antigen (HLA) class I antigens for which multiple
subtypes have been defined. It contributes about 30% of the heritability of the disease(25). The
association between HLA alleles and a given disease may be quantified by determining the
frequency of the HLA alleles expressed by individuals afflicted with the disease, then
comparing  these data with the frequency of the same alleles in the general population.
3.3.1.Spondyloarthropathy (SpA)
Spondyloarthropathy constitute a spectrum of inter related disorders that include
 Ankylosing Spondylitis (AS- the prototypical spondyloarthropathy),
 Reactive arthritis (ReA, previously known as Reiter syndrome,RS),
 Psoriatic arthritis (PsA),
 Arthritis associated with Crohn’s disease and ulcerative colitis,
 Juvenile Ankylosing Spondylitis (JAS),
 Undifferentiated spondyloarthropathy (USpA) (26).
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Spondyloarthropathy includes specific group of disorders with certain common
features, the group often termed specifically as seronegative spondylarthropathies
or seronegative spondyloarthritis.
"Seronegative" refers to that these diseases are negative for rheumatoid factor(27) ,
indicating a different pathophysiological mechanism of disease than what is commonly seen
in rheumatoid arthritis. These group of diseases involves the axial skeleton(28) and having a
negative serostatus and have an increased incidence of HLA-B27, as well as
negative rheumatoid factor and ANA .
Enthesopathy (disorder involving the attachment of a tendon or ligament to a bone) is also
sometimes present in association with seronegative Spondyloarthropathy.
As spondyloarthropathy mainly involves the axial skeleton lower back pain is the most
common clinical presentation; this back pain is unique because it decreases with activity.
Non vertebral signs and symptoms include asymmetric peripheral arthritis which is
distinct from rheumatoid arthritis,
 Arthritis of the toe interphalangeal joints,
 Sausage digits,
 Achilles tendinitis,
 Plantar fasciitis,
 Costochondritis,
 Iritis,
 Mucocutaneous lesions.
3.3.1.1.The characteristic features of SpA include :
1. Asymmetric peripheral arthritis predominantly  involving lower limbs.
2. Radiographic evidence of sacroiliitis with or without spondylitis
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3. Enthesopathy
4. Absence of rheumatoid factor
5. Absence of subcutaneous nodules and other extra articular features of RA.
6. Anterior uveitis
7. Association with psoriasis, IBD(Inflammatory Bowel Diseases), urogenital infections
8. Presence of dactylitis
9.  Increased familial incidence
10. Strong association with HLA B27
3.3.1.2.Conditions
The following conditions are typically included within the group of seronegative
spondylarthropathies:
Condition Percentage
of B27 positivity
1.Axial spondyloarthritis (including ankylosing spondylitis)                     Caucasians: 92%
African-
Americans:50%
2.Reactive arthritis (formerly known as Reiter's syndrome)                                60-80%
3.Enteropathic arthropathy or spondylitis associated with                                    60%
inflammatory bowel disease (including Crohn's disease
and ulcerative colitis)
4.Psoriatic arthritis 40-50%
5.Isolated acute anterior uveitis 50%
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6.Juvenile idiopathic arthritis 80-90%
7.Undifferentiated spondyloarthropathy (USpA)                                                 20-25%
These types have overlapping clinical features so it is very difficult to differentiate in
early stages.
The common denominator of all these is the pathological sites of inflammation which
include the Enthuses –which are sites of bony insertion of ligaments and tendon), the sacroiliac
joints and the axial skeleton, large joints of lower extremity with asymmetrical involvement
and also some extra-articular structures like eyes, skin, gut, aortic valve and conducting tissues
of heart (29).
3.4.Etiopathogenesis of Spodyloarthropathy & HLA-B27 linkage:
Ankylosing spondylitis is taken as prototype for explaining etiopathogenesis and clinical
features.Etiology of Spondyloarthropathy is unknown but involves the interaction of genetic
and environmental factors. The causes of  SpA  are multifactorial and involves a number of
inter linking pathways.
A considerable number of critical factors have been identified.
They can be classified into two groups.
1.One group consists of mediators leading to inflammation that are midstream in the pathways.
These mediators are targets of current therapies in the management.
2.The second group of factors are genetics.
Genetics contributes to more than 90% of the total cause of ankylosing
spondylitis, disease is caused by up to nine genes with multiplicative interactions among loci.
Some individuals have the tendency to develop arthritis following infection with some
bacterias due to presence of some genetic factors and  molecular mimicry between bacterial
antigens and tissue antigens.The only enteric bacterium that has been incriminated  is
Klebsiella pneumoniae(30).
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3.4.1.Genes Responsible For Development of SpA:
In the Wellcome Trust Case Control Consortium and the Australo-Anglo-American
Spondylitis Consortium studies, when these genes are ranked according to their degree of
contribution, they are listed as follows:
1.HLA-B27,
2.ERAP1 (endoplasmic reticulum amino peptidase 1, previously known as aminopeptidase-
regulating tumor necrosis factor receptor shedding 1, abbreviated as ARTS-1),
3.IL-23R (interleukin 23 receptor),
4.IL-1R2 (interleukin 1receptor, type II), and
5.ANTXR2 (anthrax toxin receptor, also known as capillary morphogenesis protein 2, or
CMG2).
The population attributable risks for the first three genes are 90%, 26%, and 9%, respectively.
Those for IL-1R2 and ANTXR2 are probably less than 5%(31).
HLA-B27 is the largest contributor for SPA. HLAB27 typing is very useful in broadening the
views of the clinical spectrum of these diseases (32). One such example is the atypical clinical
presentation of patients with back inflammation who have normal sacroiliac and spinal
radiographs (33).  Much of the investigation into the aetio-pathogenesis of these diseases has
focused on the association with HLA-B27 and the known triggering potential of certain
infectious agents.
3.4.2.Structure And Subtypes Of HLA B27:
HLA-B27 is a class I MHC molecule which consisting of
1.An alpha chain encoded in the MHC region on chromosome 6 and
2.A beta chain -β2 microglobulin which is a non glycosylated protein encoded by a
non-MHC gene from chromosome 15 .
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Upto 26 different alleles of HLA B27 have been identified coding for 24 different proteins
designated as HLA-B*2701–B*2725 (B*2722 was deleted on the discovery because it had the
same sequence as B*2706)(34). These allotypes of HLA B27 differ from one another by a few
aminoacid  substitutions and the multiple alleles may have evolved from the most widespread
subtype, B*2705. They show variation in frequency among ethnic and racial groups.
Out of over 25 subtypes of HLA B27, HLA B2705, 2702, 2704 & 2707 are clearly
associated with riskof SpA . HLA B2705 is the major sub-type present in 90% of HLA B27
positive whites and 45% of HLA B27 positive Asian Indians (35).Two subtypes, HLA B2706 (
southeast Asia) and 2709 (sardinia) are not associated with SpA (36).
2.5.Prevalence
Worldwide prevalence of spondyloarthropathy is approximately 1.9%( 37).
2.5.1.HLAB27 in normal population
The prevalence of HLA-B27 varies between populations across the world from 50%
in Haida Indians , nil in Australian Aborigines. In the UK it is about 8%. HLA-B27 is rare in
the American black population whereas in Eskimo populations prevalence rates is 25% or
more(38).
Most of the subtypes of HLA B27 appear to predispose to disease development. Up to 20% of
HLAB27 positive individuals develop Ankylosing Spondylitis (AS) or develop Reiter's
Syndrome (RS)(39).
Incidence of SpA in Eskimo and Inuit persons is highest with HLA B27 positivity of
25-40% (40) and rare in Japenese persons with a very low (<1%) prevalence of HLA B27(41).
Ankylosing spondylitis (AS) occurs more rarely in non-Caucasian populations. HLA-B27
occurs in less than I % of Japanese and black Africans population, So the disease is very rare in
the Japanese and almost unknown in the black Africans.
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In the American Indian, B27 prevalence ranges from 18% to 50%, and AS is more
frequent (42). In most populations, HLAB27 is present in more than 90% of patients and in less
than 10% of the general population(43). There are strong association with some subtypes of
HLAB27 which supports the view that the disease is due to genetically determined immune
response to environmental factors in susceptible individuals(44).
3.5.2.HLAB27 in sponyloarthropathy
It has been estimated that this HLA B27allele is responsible for up to 28% of the
aetiology of SpA(45).
In the UK, HLA-B27 is present in 90–95% of ankylosing spondylitis patients, 60–
90% of reactive arthritis patients, 50–60% of  psoriatic arthritis or inflammatory bowel disease
and spondylitis patients, and 80–90% of children with juvenile ankylosing spondylitis(46).
3.5.2.1.In Ankylosing Spondylitis:
This antigen is associated with ankylosing spondylitis in virtually in all racial
groups. However, there is some variation in the strength of the association which is weaker in
native Indonesians, Lebanese, Thais and West Africans.
Association of AS with HLA-B27 remains one of the strongest known association of
diseases with HLA-B27. In AS patients About 95% of express HLA-B27, although the
frequency of this  HLA B27 antigen in Caucasians is below 10.0%. However, the causative
role of HLA-B27 in SpA is still not fully understood ,although various studies confirmed that
the HLA-B27 molecule itself is the strongest predisposing factor for disease pathogenesis (2).
3.5.2.2.Acute Anterior Uveitis
Approximately 1% of HLA-B27 positive individuals develop acute anterior uveitis (AAU)(47)
About 20–30% of patients with ankylosing spondylitis or Reiter’s syndrome develop AAU(48).
84% of HLA-B27 positive patients with AAU have other B27-associated diseases, specifically
Reiter’s syndrome, ankylosing spondylitis or psoriatic arthritis.
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3.5.2.3.psoriatic arthritis
There is a strong association between HLA-B27 and palmoplantar pustulosis whilst
scalp psoriasis may occur less frequently in patients with B27(49,50).
3.5.3. In India
HLA B27 is positive in 83% of AS patients in south India and 94% of AS patients in
North India (51).HLA- A locus has been associated with uveitis in North India  and HLA A2
has been found in high frequency in and around Pune (52).
3.5.4. Risk In Relatives
The finding of HLA-B27 and/or a family history of spondylitis are useful in
diagnosing a Spondyloarthropathy (53). An offspring of an individual with HLA-B27 has a
50% chance of carrying the same antigen, thus conferring an overall chance of 10% developing
AS or RS if exposed to a specific environmental trigger.  The risk for B27-positivity in
relatives of B27-positive patients ranges from 25-50%. In a European population study, there is
a 16-fold increase in risk of developing ankylosing spondylitis in HLA-B27 positive relatives
compared with B27 positive individuals in the general population. (54)
HLA-B27 positive Caucasians have a 20-fold increased risk of developing any
Spondylarthropathy, particularly ankylosing spondylitis and undifferentiated spondarthritis.
Family and twin studies of ankylosing spondylitis have shown  that the genetic
susceptibility to HLA-B27  has been estimated to be 20–50% of the total. They also have a
polygenic pattern of genetic susceptibility with heritability in excess of 90%. Homozygosity
for HLA-B27 does not found to enhance the risk of developing ankylosing spondylitis(55).
3.6.Other Alleles Associated:
Other HLA alleles, particularly HLA-B60 and HLA-DR1, may predispose to
ankylosing
spondylitis either independently of B27 allele or in conjunction with it(56).
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3.7.Theories Of Hla B27 Association with SpA
Various theories are proposed to explain the association of SpA with HLA B27.
Several of them involve some form of molecular mimicry. In these theories HLA B27
functions as a T cell restriction element, as an antigen, or both:
(1) HLA B27 presents a bacterial derived peptide to HLA B27 restricted CD8 positive CTL
crossreacting with self peptides presented by HLA B27.
(2) HLA B27 molecules would present a peptide derived from HLA B27 itself with
sequencesimilarity with bacteria
(3) Peptides derived from the HLA B27 molecule would be presented by MHC class II
molecules
to CD4 positive T cells that previously have been activated by bacterial antigens.
(4) Antibodies induced by bacteria may crossreact with HLA B27 molecules, thereby initiating
an autoimmune response(57,58,59).
3.8.Current Hypotheses
Hypotheses linking the Spondyloarthropathy with HLAB27 include the following
(60):
1. HLA B27 acting as a receptor site for an infective agent that triggers inflammatory
reactions
in SPA.
2. HLA B27 being a marker for a gene on chromosome 6 which determines susceptibility to an
unknown trigger.
3.HLA B27 induces tolerance to cross-reactive foreign antigens - that is Molecular Mimicry
eg: Klebsiella, Shigella, Chlamydia, and Yersinia (61,62,63).
Most experiments attempting to identify the mechanisms of arthritis in SPA have
been carried out with the  more common B27*05 and B27*04 subtypes. Multiple hypotheses
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have been reported till now regarding  how HLA-B27 molecules mediate arthritis. At least
three hypotheses are currently under active  investigation.
3.8.1.Arthritogenic Peptide Hypothesis
This hypothesis postulates that there is a breakdown of tolerance to certain self-
peptides in the case of ankylosing spondylitis, and this breakdown is a consequence of
molecular mimicry between the self-peptides and certain pathogen-derived and arthritis-
causing peptides(64).
3.8.2.Free Heavy Chain Hypothesis
HLA-B27 molecules can exist on the cell surface as free heavy chains which contains
only α chains,  free of β2microglobulin or peptides with the classic HLA-B27 motif . They
exist as stable dimers and are capable of engaging allele-specific receptors on natural killer
(NK) cells and T lymphocytes. Receptors for these HLA-B27 free heavy chain dimers are
 KIR3DL1*001 allele of  KIRs (a family of immunoglobulin-like receptors on NK
cells and certain subsets of T cells) and
 LILRA1 and LILRB2 alleles of LILRs (a family of leukocyte immunoglobulin-like
receptors on NK cells, T and B cells, and cells of the myeloid lineage)(65).
The free heavy chain hypothesis postulates that engagement of these receptors will generate
arthritis-causing events in SpA.
3.8.3.Unfolded Protein Hypothesis
HLA-B27 heavy chains have more prolonged retention times inside the ER than
other common HLA alleles. In addition more partially misfolded and unfolded forms of HLA
B27 are found inside the ER compared with other HLA alleles due to aberrant disulfide bond
formation and multimer formation among the heavy chains and among others. These partially
folded or misfolded HLA-B27 proteins remain for a time sequestrated inside the ER, being
complexed with
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chaperones such as the “immunoglobulin heavy chain–binding protein” abbreviated as BiP
(GRP78, 78-kD glucose-regulated protein).
BiP is a sensor for accumulation of misfolded proteins.So it initiates several ER
processes, which together are termed unfolded protein response (UPR)(66).UPR along with
HLA-B27 polarizes the cells in response to lipopolysaccharide of some bacterias to cross-talk
with the cytokine systems by generating interleukin (IL)-23.
HLA-B27 induces an unfolded protein response which in conjunction with
activation by pattern recognition receptors (PRRs) such as those for lipopolysaccharide will
generate proinflammatory cytokines in more amount as to cause arthritis(67).
3.8.4.Molecular Mimicry
The hypothesis which has received most attention is molecular mimicry between
HLA B27 antigen and microbial antigens. Klebsiella pneumoniae is a frequently isolated
organism in faeces of AS patients with an active disease or with acute anterior uveitis and is
also increased in asymptomatic AS patients (68). AS patients with an active disease have an
increased level of IgA anti-Klebsiella antibodies (69), and the presence of faecal Klebsiella is
associated with elevation of serum C-reactive protein (70).In a study of Geczy and co-workers
on the association between HLA-B27, AS and Klebsiella (71) , Their studies showed that HLA
B27
positive AS patients had significantly impaired in vitro Iymphoproliferative responses to
Klebsiella antigens when compared with HLA B27 positive or negative normal controls. They
also observed that antibodies raised in rabbits against a certain Klebsiella isolate specifically
lyses HLA B27 positive Iymphocytes of AS patients (72).
3.9.SPA in males and females
Clinically, SpA  is more common in males, with a reported male-to-female ratio of about
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2 : 1 to 3 : 1. However, studies on the genetic marker HLA-B27 suggests that, on the basis of
radiographs of the SI joints, prevalence rates are about equal in both sexes(72).
3.10.Other Factors Responsible For SpA
Such as environmental factors, and other genetic factors, including those within the
major histocompatibility complex (MHC) class I—HLA-B60/HLA-B40, HLA-B39, HLA-
B14and HLA-B15 and class II DRB1 alleles also have an impact on the onset of the disease,.
There are more
than 40 genes implicated in the pathogenesis of SpA, which affects the clinical manifestations,
including the age of onset and the duration and severity of the disease(73).
3.11.SPECIFIC DISEASES
3.11.Ι.Ankylosing Spondylitis
Ankylosing spondylitis (AS) is a disease that typically affects the structures of the
spine and the  entheses. In the spine, the areas involved are the sacroiliac joints, the vertebral
bodies, and the  zygapophyseal joints .
Enthesitis- is an extraarticular manifestation defined as inflammation at the anatomic
zones where ligaments or tendons insert into underlying bone. Examples include the Achilles
tendon and the fascia plantaris.
Both inflammation and progressive ankylosis are the two processes  that are
independent of each other, but both can lead to loss of mobility in AS(74). They considered to
be separate targets for therapeutic intervention.
3.11.1.1.Types of AS:
 Axial AS
There is Involvement of spine, sacroiliac joints.
 Peripheral AS
Here common joints Involved are hip joint, knee joint and ankle joint.
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Radiographic sacroiliitis is considered as a hallmark and is found in more than 90%
of patients. The inflammation of the sacroiliac (SI) joints and the spine eventually may lead to
bony ankylosis. Ankylosis of the spine tends to appear in late stages of the disease. Many
patients with
AS have onset of back pain mostly during their third decade of life. It takes, on average of 6 to
8 years between the onset of back pain and establishing a definite diagnosis of AS. This
diagnostic delay is mainly by late appearance of definite radiographic sacroiliitis on
conventional plain radiographs.
Thus many patients at an early stage may not show definite evidences of sacroiliitis on
radiographs but typically present with characteristic clinical symptoms of AS. Therefore in
such patients with suspected early AS, sacroiliitis may best be detected on MRI than
convensional radiography(75).
3.11.1.2.Pathology
Characteristic pathologic features  include inflammation in axial joints, large
peripheral  joints, and entheses along with inflammation in subchondral bone marrow.
Reparation process is also characteristic in terms of the development of chondroid metaplasia,
followed by calcification of cartilage and formation of bone, particularly in the axial joints. Fat
metaplasia in the axial skeleton at sites of prior inflammation is frequently observed on MRI.
Entheseal involvement most frequently occurs at sites rich in fibrocartilage such as the
Achilles tendon. Inflammation and chronic cellular infiltration of soft tissues are relatively
SpArse but may be extensive within the adjacent subchondral bone, particularly in HLA B27+
individuals(76).
Synovial studies have revealed that the type of inflammation is strongly different
from that observed in RA, with increased vascularity, increased infiltration with innate immune
cells, and absence of specific features of T and B cell autoimmunity(77).
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3.11.1.3.Clinical Manifestations
3.11.1.3.1.Skeletal Manifestations
 Low Back Pain and Stiffness
The pain is initially felt primarily deep in the gluteal region, is dull and difficult to
localize, and is insidious in onset. The pain can be severe at this early phase of the disease; it
localizes in the SI joints but is occasionally referred toward the iliac crest or greater
trochanteric region or down the dorsal thigh. Radiation of buttock pain may suggest root
compression of the sciatic nerve.
The buttock pain typically alternates from side to side. Coughing, sneezing, or other
maneuvers that cause a sudden twist of the back may increase the severity of pain. Although
the pain is often unilateral or intermittent at first, within a few months it usually becomes
persistent and bilateral and the lower lumbar area becomes stiff and painful. The pain is
associated with a feeling of low back stiffness that is worse in the morning and may awaken
the patient from sleep,
Particularly during the second half of the night. Many patients do not differentiate between low
back pain and stiffness. The morning stiffness may last up to 3 hours.
Both the stiffness and the pain usally do not improve with rest but tend to be eased
by a hot shower, an exercise program, or physical activity. Fatigue as a result of chronic back
pain and stiffness may be an important problem and can be accentuated by sleep disturbances
due to these symptoms.
characters of Inflammatory Back Pain in Ankylosing Spondylitis and  other Axial
Spondyloarthritis
 Onset of complaints before age 45
 Duration of symptoms more than 3 months (chronic pain)
 Located at the lower back
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 Alternating buttock pain
 Insidious onset of complaints
 Awaking due to back pain during the second half of the night
 Morning stiffness for at least 30 min
 No improvement of back pain with rest
 Improvement after exercises
 Improvement with use of nonsteroidal anti inflammatory agents
In children usual presenting features of a spondyloarthropathy are peripheral
arthritis and enthesitis, and low back pain is not frequent.
 Chest Pain
With subsequent involvement of the thoracic spine (including costotransverse and
costovertebral joints) and the occurrence of enthesitis at the costosternal and manubriosternal
joints, patients may experience chest pain which is accentuated by coughing or sneezing,
sometimes characterized as “pleuritic pain.” The chest pain is often associated with tenderness
over the sternocostal or costosternal junctions. Chest pain occurs often in HLA-B27+ relatives,
even in the absence of radiographic evidence of sacroiliitis(76)
 Tendernes
Extra-articular tenderness is a prominent complaint in some patients,especialy in
young patients. These lesions are due to enthesitis. Common tender sites are the costosternal
junctions, spinous processes, iliac crests, greater trochanters, ischial tuberosities, tibial
tubercles, and heels (Achilles tendinitis or plantar fasciitis). Radiographically, bone spurs may
develop at these sites.
 Other Joint involvement
Hips and shoulders are the most frequently involved extra-axial joints in AS.Hip
disease is more common in Algeria, India, and Mexico. It is relatively more common as a
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presenting manifestation if the disease starts in childhood (juvenile AS). These children with
hip disease are mostly HLA-B27+, and they are serologically negative for antinuclear
antibodies.
The knee joint may also be affected in AS, often as an intermittent effusion. The
temporomandibular joint is involved in about 10% of patients(78).
3.11.1.3.2.Extraskeletal Manifestations
 Eye Disease
Acute anterior uveitis or iridocyclitis is the most common extra-articular
manifestation of AS, occurring in 25% to 30% of patients at some time during the course of the
disease. The onset of eye inflammation is usually acute and typically unilateral, but the attacks
may alternate. The eye is red and painful, with visual impairment. Photophobia and increased
lacrimation may be present. If  remains untreated or if treatment is delayed, posterior synechiae
and glaucoma may develop. Most attacks subside in 4 to 8 weeks without any sequelae if early
treatment is provided. Acute anterior uveitis is more common in HLA B27 positive patients
than HLA B27 negative patients with AS(78).
Relatives who have acute anterior uveitis seem to be at higher risk for AS. The
calculated incidence of acute anterior uveitis in a Swiss family study was 89 attacks per 1000
patient-years for AS patients, but only 8 per 1000 person-years among healthy B27+
relatives(79).
 Cardiovascular Disease
Manifestations of cardiac involvement include ascending aortitis, aortic valve incompetence,
conduction abnormalities, cardiomegaly, and pericarditis.
Aortic incompetence was noted in 3.5% of patients who had the disease for 15 years and in
10% after 30 years. Inflammation and dilation of the aorta are the main causes of aortic valve
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incompetence. Aortic regurgitation occurs in 2–10% of patients with ankylosing spondylitis,
and cardiac conduction abnormalities including atrioventricular and intraventricular blocks
have been found in one-third of patients with spondylitis. Cardiac conduction disturbances are
seen with increasing frequency with the passage of time, occurring in 2.7% of those with
disease of 15 years’ duration and in 8.5% after 30 years(80).
Both aortic incompetence and cardiac conduction defects occur twice as often in patients with
peripheral joint involvement.
In AS the prevalence of myocardial infarction is increased (4.4% in AS patients
compared with 1.2% in the general population in a Dutch study)(81).
 Pulmonary Disease
Lung involvement is a rare and late manifestation of AS. It is characterized by slowly
progressive fibrosis of the upper lobes of the lungs, appearing, on average, 2 decades after
the onset of AS. Patients may complain of cough, dyspnea, and sometimes hemoptysis. Upper
lobe fibrosis is the lung condition best known to correlate with HLA-B27(82).
 Neurologic Involvement
Neurologic complications of AS can be caused by fracture, minstability,
compression, or inflammation. Traffic accidents or minor trauma can cause spinal fractures.
The C5-C6 or C6-C7 level is the most commonly involved site,more commonly in patients
with spondylitis and
peripheral arthritis than in those with exclusively axial involvement(83).
The cauda equina syndrome is a rare but serious complication of long-standing AS. The
syndrome affects lumbosacral nerve roots.
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 Renal Involvement
IgA nephropathy has been reported in many patients with AS. These patients often
have an elevated immunoglobulin (Ig)A level (93%) and renal impairment (27%) at
presentation(84).
Microscopic hematuria and proteinuria may occur in up to 35% of patients. The significance of
these findings in terms of subsequent deterioration of renal function is unclear(85). Secondary
Amyloidosis  is a rare complication. (86).
 Osteoporosis
Osteopenia is seen in the early stages of AS(87). In patients with this disease,
osteoporotic deformities of the thoracic spine contribute significantly to abnormal posture,
particularly fixed hyperkyphosis(88). Radiographic damage to the cervical and lumbar spine,
thoracic wedging, and disease activity are determinants of hyperkyphosis in AS(89).
3.11.1.4.Physical Findings
 Spinal Mobility- limitation of motion of the lumbar spine.Early loss of the normal
lumbar lordosis is often the first sign and is easily assessed on inspection.
 Chest Expansion - Reduction below 5 cm in young persons with an insidious onset of
chronic, inflammatory low back pain strongly suggests AS
 Enthesitis - Examination of the ischial tuberosities, greater trochanters, spinous
processes, costochondral and manubriosternal junctions, supraspinatus insertion, and
iliac crests can determine the presence of enthesitis. Heel pain, especially when getting
out of bed, is a characteristic manifestation of Achilles and plantar fasciitis enthesitis.
 Sacroiliitis - Direct pressure over the SI joints may elicit pain, These signs may also be
negative in early disease or may become negative in late stages as inflammation is
replaced by fibrosis or bony ankyloses
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 Posture
Over the course of the disease, the patient may lose normal posture. After many years
of progression, the entire spine may become increasingly stiff, with loss of normal posture
from gradual loss of lumbar lordosis and the development of thoracic kyphosis.
The abdomen becomes protuberant; breathing is primarily by diaphragmatic action.
These typical deformities usually occur after 10 years of disease duration or more.
3.11.1.5.AS in pregnancy
Fertility among female patients with AS is normal(90). 50% to 60% of  patients do
not experience major changes in disease activity during pregnancy, but an increase in morning
stiffness and low back pain, particularly at night, may occur at about the 20th week of gestation
and last for a few days to weeks(91).
In about 50% of patients, an exacerbation of symptoms is occur within the first half
year after delivery. Sacroiliitis including complete ankylosis of the SI joints does not constitute
a contraindication for vaginal delivery.
Epidural anesthesia is usually possible because most patients have a rather short
duration of disease and do not have extensive spinal syndesmophytes.
The fetal outcome is not impaired in patients with AS. Every pregnancy in patients with this
disease should be considered potential high risk.
Diagnostic Features of Ankylosing Spondylitis
 Chronic inflammatory spinal pain
 Alternate buttock pain
 Chest pain
 Acute anterior uveitis
 Synovitis (asymmetric ,predominantly of lower limbs)
 Enthesitis (heel, plantar)
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 Radiographic sacroiliitis
 Positive family history of ankylosing spondylitis
 Chronic inflammatory bowel disease
 Psoriasis
3.11.2.Reactive Arthritis
Arthritis that follows infection and shares features with other forms of
spondyloarthritis(92). These include clinical features such as frequent evidence of enthesitis, in
addition to arthritis, extra-articular features, particularly those involving eyes and skin, and, as
required for a spondyloarthritis family member, a clear association with HLA-B27(93). Using
this definition, a relatively small list of bacteria are common triggers of reactive arthritis, anda
longer “tail” of infections have occasionally been reportedas causes. These organisms
principally infect the gastrointestinal and genitourinary tracts.
3.11.2.1.Reiter’s syndrome or Reiter’s triad—consisting of urethritis, conjunctivitis, and
arthritis.
Urethritis is common in patients whose reactive arthritis is triggered by enteric infection,
especially HLA-B27+patients(94).
Reiter’s syndrome is a best a synonym for reactive arthritis
3.11.2.2.Enteropathic arthritis
Reactive arthritis secondary to gastrointestinal infection is sometimes bracketed with
spondyloarthritis associated with inflammatory bowel disease as enteropathic
arthritis(95).Enteropathic arthritis is an ill-defined overlap term, which often includes other
forms of arthritis that do not have classic features of spondyloarthritis but occur in relation to
gastrointestinal disorders. Examples include Whipple’s disease and celiac disease.
Organisms Associated with Reactive Arthritis
Common Gastrointestinal Pathogens
Salmonella species
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Campylobacter jejuni and Campylobacter coli
Yersinia enterocolitica and Yersinia pseudotuberculosis
Shigella flexneri; less commonly, Shigella sonnei or Shigella dysenteriae
Clostridium difficile
Genitourinary Pathogens
Chlamydia trachomatis
?Mycoplasma species
Respiratory Pathogens
Chlamydia pneumoniae
Reported
Mycobacterium bovis bacillus Calmette-Guérin
Enterotoxigenic Escherichia coli and many others.
3.11.3.Undifferentiated Spondyloarthritis
Obvious overlap has been noted between different members of the spondyloarthritis
family. By definition, patients with undifferentiated spondyloarthritis have arthritis that fails to
satisfy diagnostic or classification criteria for one of the other forms.
3.11.4.Psoriatic Arthritis
Psoriatic arthritis is a member of the spondyloarthropathy family and may be
defined as an inflammatory arthropathy associated with psoriasis and usually negative for
rheumatoidfactor. Psoriatic arthritis should be suspected in a patient with an asymmetric joint
distribution pattern who may have additional clinical features, such as dactylitis, enthesitis, or
inflammatorytype back pain, and who is negative for rheumatoid factor.
Among patients with psoriasis, 7% to 42% develop arthritis. The reported prevalence of
psoriatic
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arthritis ranged from 0.056% to 0.28% in a large population-based study in the United
States(96).
3.12.Diagnosis
Clinical manifestations of SpA  usually begin in late adolescence or early
adulthood; only rarely do they begin after age 40 years(97).
The diagnosis of AS at an early stage of disease depends primarily on a careful history and
physical examination.
Two features of the history are critical:
(1) the presenceof inflammatory low back pain and stiffness and
(2) a positive family history for AS.
Amor Criteria for Spondyloarthritis
Lumbar or dorsal pain during the night, or morning
stiffness of lumbar or dorsal spine
1
Asymmetric oligoarthritis 2
Buttock pain 1
Alternating buttock pain 2
Dactylitis of finger or toe 2
Heel pain or other well-defined enthesopathy 2
Iritis 2
Nongonococcal urethritis or cervicitis within 1 mo of
arthritis onset
1
Acute diarrhea within 1 mo of arthritis onset 1
Psoriasis, balanitis, or inflammatory bowel disease 2
Radiology
Sacroiliitis (grade ≥2 if bilateral; grade ≥3 if unilateral)
3
Genetic Background
HLA-B27+ or family history of ankylosing spondylitis,
reactive arthritis, uveitis, psoriasis, or inflammatory
bowel disease
2
Response to Treatment
Good response to NSAIDs within 48 hr, or relapse within
48 hr if NSAIDs withdrawn 2
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For a definitive diagnosis of spondylarthritis, ≥6 points is required; 5 points indicates probable
spondyloarthritis
Proposed Criteria for Inflammatory Back Pain in Young to Middle-aged Adults*
withChronic Back Pain
Morning stiffness of at least 30 min duration
Improvement of back pain with exercise but not with rest
Awakening because of back pain during second half of night only
Alternating buttock pain
European Spondyloarthropathy Study Group Criteria for Spondyloarthritis
For patients with:
Inflammatory spinal pain
or
Synovitis that is asymmetric or is present predominantly in the lower limbs
+ ≥1 if:
Family history of spondyloarthropathy
Psoriasis
Inflammatory bowel disease
Urethritis, cervicitis, or acute diarrhea within 1 mo of onset of arthritis
Alternating buttock pain
Enthesitis
Sacroiliitis
A definite diagnosis of AS is usually established by radiographic evidence of
bilateral sacroiliitis. The plain anteroposterior view of the pelvis is usually adequate for
diagnostic purposes. However, in young patients with inflammatory chronic back pain, a
positive HLA-B27 test increases the likelihood of having AS, particularly if imaging of the SI
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AS rarely develops after age 40; however, late-onset AS does occur. In this case,
there may be little or no clinical involvement of the axial skeleton initially, but patients may
show moderate oligoarthritis with low cell counts in the synovial fluid and pitting edema of the
lower limbs(98).
At the other end of the age scale, juvenile-onset AS is common among young
patients with spondyloarthritis. Such patients tend to have enthesitis and peripheral arthritis,
which may be severe and disabling.
3.12.1.Imaging Studies
3.12.1.1.Conventional Radiography
The typical radiographic changes  are seen primarily in the axial skeleton, especially in the SI,
discovertebral, apophyseal, costovertebral, and costotransverse joints. They are symmetric and
consist of  blurring of the subchondral bone plate, followed by erosions and sclerosis of the
adjacent bone. The cartilage covering the iliac side of the joint is much thinner than that
covering the sacral side.
Therefore the erosions and subchondral sclerosis are typically seen first and tend
to be more prominent on the iliac side.After several years, there may be complete bony
ankylosis of
the SI joints, with resolution of bony sclerosis.
Grading of radiographic sacroiliitis according to the New York criteria
Grading of Sacroiliitis: New York Criteria
Grade 0, normal
Grade 1, suspicious
Grade 2, minimal sacroiliitis
Grade 3, moderate sacroiliitis
Grade 4, ankylosis
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Bony erosions and osteitis (“whiskering”) at sites of osseous attachment of tendons
and ligaments are frequently seen, particularly at the calcaneus, ischial tuberosities, iliac crest,
femoral trochanters, supraspinatus insertion, and spinous processes of the vertebrae.
This combination of destructive osteitis and repair leads to “squaring” of the vertebral bodies.
This squaring is associated with gradual ossification of the annulus fibrosus and eventual
“bridging” between vertebrae by syndesmophytes(99).
There are often concomitant inflammatory changes, ankylosis in the apophyseal joints, and
ossification of the adjacent ligaments. In a number of patients, this may ultimately result in a
virtually complete fusion of the vertebral column (“bamboo spine”). This lacks sensitivity in
early sacroiliitis because it only detects structural abnormalities that are the consequence of
inflammation.
3.12.1.2.Computed Tomography
To detect bone abnormalities such as sclerosis and erosion  sooner than plain
radiography but its use is limited by
 Radiation exposure
 Does not detect changes in softtissues or bone marrow (100)
3.12.1.3.Magnetic Resonance Imaging
MRI sequences that are used in routine practice to image the SI joint can detect
sacroiliitis in 50% of patients with preradiographic SpA(100).
These sequences include
1. Fat saturating techniques, such as short tau inversion recovery (STIR), that are very
sensitive in the detection of bone marrow edema, which is a frequent finding in AS-
related inflammation of the musculoskeletal system
2.The T1-weighted sequence allows detection of erosions and fat infiltration, which
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may occur early in disease and is associated with resolution of inflammation.
Diagnostic MRI should
include both sequences.
3.12.2.Laboratory Tests
1.An elevated ESR or CRP is reported in up to 75% of patients, but it may not correlate with
clinical disease activity(101).
2. A mild normochromic anemia may be present in 15% of patients.
3.Elevation of serum alkaline phosphatase (derived primarily from bone) is seen in some
patients but is unrelated to disease activity or duration.
4.Some elevation of serum IgA is frequent in AS. Its level correlates with acute-phase
reactants.
5.Active disease is associated with decreased lipid levels, particularly high-density lipoprotein
cholesterol, resulting in a more atherogenic lipid profile(102).
3.12.2.1.Microbiology
3.12.2.1.1.Culture and Other Methods of Detecting Bacteria.
The aim is to get a evidence to implicate a reactive arthritis–associated
microorganism.
For gastrointestinal infection, stool culture should be carried out; organisms such
as Salmonella and Yersinia may persist in the gut for several weeks after gastroenteritis has
resolved. Yersinia has the unusual property of growing at 4° C, which allows improved
detection of the organism by maintaining the stool sample at 4° C for 24 to 48 hours prior to
culture; microbiology laboratories should be informed that Yersinia infection is being
considered to allow them to do this. Stool culture for Yersinia is also appropriate in patients
without gastrointestinal symptoms because symptoms are often mild in infection with this
organism.
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For genitourinary infection, swabs should be obtained from the urethra or
vagina for culture of Chlamydia trachomatis and, if indicated, from the throat and rectum.
However, in view of the difficulty involved in culturing chlamydiae, nucleic acid amplification
techniques (ligase chain reaction [LCR], PCR) are generally preferred and can be performed on
urine samples or by self administered swabs, both of which are acceptable to patients.
Use of PCR to identify Chlamydia in synovial fluid has not yet been developed
sufficiently(103). PCR is also helpful in establishing a diagnosis of Chlamydia pneumoniae
infection when arthritis is seen in association with respiratory tract infection. The presence of
chlamydiae can be detected in urine or sputum by means of an enzyme-linked immunosorbent
assay (ELISA) to detect chlamydial lipopolysaccharide (LPS)
3.12.2.1.2.Serology
Although culture or direct demonstration of the organism is preferred, in some
circumstances serology can provide reliable evidence of a preceding infection.Its effectiveness
depends very much on the frequency of infection in the community and therefore on the
proportion of subjects with pre-existing antibodies.
For Salmonella species, and increasingly for Campylobacter, antibodies are
commonly detected in healthy subjects because of a high level of community exposure to these
organisms.
In these cases therefore, diagnosis will rest, at best, on an increased titer of pathogen-specific
antibodies in acute and convalescentsera. Because patients may present to rheumatologists in
the convalescent phase, as far as the triggering infection is concerned, this substantially
decreases the utility of serology in diagnosing these infections.
In contrast, infection with Yersinia or Shigella is not prevalent in Western societies,
so that detection of specific antibodies carries greater significance even if immunoglobulin
(Ig)M antibodies or a fourfold increase in titer cannot be demonstrated.
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For detection of chlamydial infection, serology generally has not proved reliable.
Micro-immunfluorescence tests can be carried out, in which dilutions of sera are applied to
multi-well slides containing organisms; this is regarded as the “gold standard” for Chlamydia
serology(103). However, again the prevalence of antibodies in the population is high,
particularly for C.pneumoniae in older subjects. Individual recombinant chlamydial antigens
have been used to devise additional serologic tests, but none has yet been established for
general use.
3.13.MANAGEMENT
3.13.1.Physiotherapy
physiotherapy in the form of exercises is effective, at least in the short term (up to 1
year).
The program, which consisted of hydrotherapy, exercises, and sporting activities twice weekly
for 3 hours per session, resulted in improved overall health and less stiffness, as reported by the
patient(104)
An intensive 3-week Spondyloarthritis exercise therapy program resulted in marked
improvement in both subjective and objective assessments that lasted for up to 9 months.
The optimal management of patients with AS requires a combination of nonpharmacologic and
pharmacologic treatment modalities
 General Treatment
The treatment of patients with AS should be tailored according to:
The current manifestations of the disease (axial, peripheral, entheseal, extra-articular symptoms
and signs)
The level of current symptoms, clinical findings, and prognostic indicators
The general clinical status (age, gender, comorbidity, concomitant medications, psychosocial
factors)
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 Disease Monitoring
The disease monitoring of patients with AS should include:
a.Patient history (e.g., questionnaires)
b.Clinical parameters
c.Laboratory tests
d.Imaging
The frequency of monitoring should be decided on an  individual basis depending on:
a.Course of symptoms
b.Severity
c.Treatment
3.13.2. Nonpharmacologic Treatment
The cornerstone of nonpharmacologic treatment of patients with AS is patient
education and regular exercise.Home exercises are effective. Physical therapy with supervised
exercises, land or water based, individually or in a group, should be preferred as these are more
effective than home exercises.
3.13.3. Extra-articular Manifestations and Comorbidities
The frequently observed extra-articular manifestations (e.g., uveitis, psoriasis,and
inflammatory bowel disease) should be managed in collaboration with the respective
specialists
3.13.4. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
NSAIDs, including coxibs, are recommended as first-line drug treatment for AS patients with
pain
and stiffness Continuous treatment with NSAIDs is preferred for patients with persistently
active, symptomatic disease,Cardiovascular, gastrointestinal, and renal risks should be taken
into account when prescribing NSAIDs.
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3.13.5. Analgesics
Analgesics, such as paracetamol and opioid drugs, might be considered for residual
pain after previously recommended treatments have failed or contraindicated, and/or are poorly
tolerated.
3.13.6. Glucocorticoids
Corticosteroid injections directed  to the local site of musculoskeletal inflammation
may be considered.
3.13.7. Disease-modifying Antirheumatic Drugs (DMARDs)
There is no evidence for the efficacy of DMARDs, including sulfasalazine and
methotrexate, for the treatment of axial disease .Sulfasalazine may be considered in patients
with peripheral arthritis.
3.13.8. Anti–Tumor Necrosis Factor (TNF) Therapy
Anti-TNF therapy should be given to patients with persistently high disease activity
despite conventional treatments according to the ASAS recommendations.There is no evidence
to support the obligatory use of DMARDs before or concomitant with anti-TNF therapy in
patients with axial disease.
There is no evidence to support a difference in efficacy of the various TNF
inhibitors on the axial and articular/entheseal disease manifestations, but in the presence of
inflammatory bowel disease a difference in gastrointestinal efficacy needs to be taken into
account.
Switching to a second TNF blocker might be beneficial, especially in patients with loss of
response.
The rationale is based on the finding of TNF expression in SI joint biopsies of AS
patients, the observation that overexpression of TNF leads to sacroiliitis.
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Four anti-TNF agents are of proven benefit in AS according to pivotal phase III trials
infliximab, etanercept, adalimumab, and golimumab.
 Infliximab - is an IgG1 chimeric monoclonal antibody with the Fab portion derived
from the mouse. It is given in a dose of 3 to 5 mg/kg every 6 to 8 weeks after loading at
0,
2, and 6 weeks.
 Etanercept - is a recombinant 75-kD TNF receptor IgG1 fusion protein that is self-
administered by subcutaneous injection either once (50 mg) or twice (25 mg) weekly.
 Adalimumab and golimumab - are human monoclonal antibodies that are self-
administered by subcutaneous injection on alternate weeks (40 mg) or monthly (50
mg), respectively.
None require concomitant therapy with methotrexate.
There is no evidence to support the use of biologic agents other than TNF inhibitors in AS.
3.13.9. Surgery
Total hip arthroplasty should be considered in patients with refractory pain or
disability
and radiographic evidence of structural damage, independent of age.
Spinal corrective osteotomy may be considered in patients with severe disabling deformity
3.14. Changes in the Disease Course
If a significant change in the course of the disease occurs, causes other than
inflammation, such as a spinal fracture, should be considered and appropriate evaluation,
including imaging,should be performed.
3.15.Outcome
The course of AS is highly variable, characterized by spontaneous remissions and
exacerbations. Its prognosis has generally been considered rather favorable. The disease may
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run a relatively mild or self-limited courseOverall, the first 10 years of disease are particularly
important with respect to subsequent outcome. Most of the loss of function among patients
with AS occurs within this period and is associated with the presence of peripheral arthritis,
spinal radiographic changes, and development of a so-called bamboo spine(105).
Seven variables were associated with disease severity if these factors occurred within the first 2
years of follow-up.
These factors, are as follows:
 Arthritis of hip joints
 ESR more than 30 mm/hr
 Poor efficacy of nonsteroidal anti-inflammatory drugs (NSAIDS)
 Limitation of lumbar spine
 Sausage-like digits
 Oligoarthritis
 Onset before age 16 years(106).
3.16.Detection Methods For HLA B27
Now there are 3 methods most fasionable for detection of HLA B27
1.Microlymphocytotoxicity (MLCT)
2.Flowcytometry
3.polymerase chain reaction (PCR)
3.16.1.Microlymphocytotoxicity (MLCT)
Here  3 different antisera against HLA-B27 were used. Peripheral blood lymphocytes
are collecte d basedAnd  inoculated into the wells of a plate into which Antiserum  previously
had been inoculated into those wells, will react with lymphocytes which have HLA-B27
antigen on their surface, and make them susceptible to become killed by rabbit complement.
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The eosin stain penetrates into the mortal cells and makes them distinguishable from unstained
live lymphocytes
under the inverted microscope(107).
sensitivity of this technique is 83.3%. Thus, the specificity of this method is 100%.
Furthermore, the positive and negative predictive values of MLCT were 100% and 88.1 %
respectively.
3.16.2.Flowcytometry
Peripheral blood mononuclear cells were stained with monoclonal antibodies
recognizing epitopes of HLA-B27 (Anti-HLA-B27 fluorescein isothiocyanate (FITC)/CD3
phycoerythrin (PE) monoclonal antibody. Lymphocytes were gated according to size and
granularity, and analyzed separately. Samples with a median fluorescence 1 (FLl ) channel
result greater than or equal to the decision marker should be considered HLAB27 positive.
Samples with a median channel result lower than the decision marker should be considered
HLA-B27 negative. FL l is a signal from anti-HLA-B27 FITC( 107).
sensitivity of flow cytometry is 100%.The specificity, positive and negative predictive
values of flowcytometry were calculated as 94.6%, 93.8% and 100% respectively.
A major disadvantage to serological methods for HLA B27 antigen detection is the cross-
reactivity of the antibodies used with different HLA antigens. To diminish the potential risk of
false positive results, alternative methods were developed based on analysis of the genes
coding for the HLA-B antigens.Flow cytometry is rapid and relatively inexpensive, but lacks
specificity especially in the presence of antigens that cross-react with HLA-B27, such as HLA-
B7 (108).
3.16.3.HLA-B27- specific PCR
DNA was directly prepared from peripheral blood (with EDTA) with salting out method.
DNA was amplified using oligonucleotide primers specific for exon 3 of the HLA-B27 gene
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Results were analyzed.
PCR is a ” gold standard method” with sensitivity of 100% and specificity of 100%
Identification of HLA-B27 by PCR supports the diagnosis of ankylosing spondylitis in
symptomatic individuals and negative results exclude the diagnosis (109).
Serological techniques such as microcytotoxicity and flow cytometry for testing HLA-B27
require viable cells that adequately express HLA-B27 and may give false negative results if
HLA-B27 is down regulated or ‘‘masked’
3.17.Diagnostic utility
The usefulness of a positive result will be greatest in populations which have a low
general prevalence of HLA-B27 and yet its association with ankylosing spondylitis is strong
like japan. For the other spondarthritides, which are less strongly linked with HLA-B27,
diagnosis is primarily based on the associated clinical features.
In practice, typing for HLA-B27 can be helpful in a patient complaining of low back
pain of an inflammatory character in the absence of radiological signs of sacroiliitis or in
patients with an asymmetrical oligoarthritis but without other features of spondarthritis.
Likewise, testing for HLA-B27 can help to differentiate between alternative aetiologies in iritis
and aortic regurgitation(110).
A positive HLA-B27 test means that the person tested is at increased risk of developing
certain autoimmune diseases. If the person has symptoms such as chronic pain, inflammation,
and/ or degenerative changes to bones (as seen on X-ray), then it supports a diagnosis
of ankylosing spondylitis, reactive arthritis, or another autoimmune disorder that is associated
with the presence of HLA-B27. This is especially true if the person is young, male, and if he
experienced his first symptoms before the age of 40.
If an HLA-B27 test is negative, then the marker was not detected. This does not mean,
however, that the person tested does not have the suspected condition since people who do not have the
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HLA-B27 antigen can also develop these autoimmune diseases. Likewise, someone who has the HLA-
B27 antigen will not necessarily develop one of these conditions. Researchers are trying to determine
what factors contribute to the higher likelihood of people with HLA-B27 developing these particular
diseases and what actually triggers them(111). HLA testing helpful in young patients with chronic
inflammatory back pain, a positive HLA-B27 test increases the likelihood of having AS later, if
imaging of the SI joints does not provide conclusive results(100).
3.18.Prognostic Value
Whereas HLA-B27 does not  influence the severity of Ankylosing spondylitis(112)
but in psoriatic spondylarthropathy it may determine susceptibility to the conditionand also its
clinical expression(113). It correlates most strongly with isolated axial disease and also it may
confer some protection against peripheral joint erosions.
Patients with Reiter’s disease and Yersinia and Salmonella triggered reactive arthritis who are
HLA-B27 positive have more severe acute disease, more extra-articular features and more
frequent chronic back pain and sacro-iliitis(114).
In Clamydia trachomatis reactive arthritis, who are HLA-B27 positive will have more severe
or chronic disease could be due to lower concentrations of interferonγ in the synovial fluid of
patients than those who are HLA-B27 negative, with consequent impaired clearance of
infective agents(115).
In cardiac disease, the relative risk that a HLA-B27 positive patient will need a permanent
pacemaker has been calculated to be 6.7 compared with a patient who has other B alleles. This
association is not, however, present in female patients.
A poor outcome of back surgery has been found in patients possessing HLA-
B27.48 but it was not clear(116).
Atlanto-axial subluxation can occur in both rheumatoid arthritis and ankylosing
spondylitis. HLA-B27 positive patients with rheumatoid arthritis have about twice the risk of
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developing subluxation of the cervical spine and an almost threefold risk of subaxial
subluxation(117). Thus, HLA-B27 may be a useful prognostic indicator for the later
development of instability of the cervical spine and its complications in rheumatoid arthritis.
Whether or not certain HLA antigens will be present is genetically
determined. Genes that are passed from parents to their children control the production of those
antigens. If two members of the same family are HLA-B27 positive and one of them develops
a disease associated with HLA-B27, then the other person is at an increased risk of developing
a similar disease. HLA-B27 positivity is a highly useful predictor of early sacroiliitis.
So the aim of this study was to investigate the frequency of HLA-B27 antigen among
suspected SpAs patients as well as healthy people by PCR.
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4. MATERIALS AND METHODS
4.1. Study group
In the present study 50 subjects with history suggestive of  seronegative
Spondyloarthropathy ( Rheumatoid factor negative and Anti nuclear antibody negative)
attending rheumatology clinic in Tirunelveli Medical College, Tirunelveli were selected as
study group,study period was from April 2016 to June 2017
4.1.1. Inclusion criteria
Patients in the age group of 14years to 65years of both sex with history suggestive of
Spondyloarthropathy like
1. Historyof back pain or buttock pain for 3months or more
2. Alternate buttock pain or back pain more in morning improved by exercise
3.Pain not relieved by taking rest
4.Family history of HLA B 27 Positivity or Spondyloarthropathy
4.Heel or plantar pain (Enthesitis)
5.Back pain associated with anterior uveitis, psoriasis, inflammatory bowel disease
4.1.2.Exclusion criteria
1. Patients with back pain diagnosed as having rheumatoid arthritis, SLE and other
Connective tissue diseases (rheumatoid factor positive, ANA positive)
2. Patients having other infectious cause for backpain
3. Patients having osteoporosis
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4.2. Control group
Normal persons without back pain of both sexes between the age group of 20years to
50years were selected to detect the prevalence of HLAB27 in normal population in this region.
4.3.Ethical clearance and Informed consent :
The Ethical committee clearance was obtained from our institution and informed
consent was obtained from all patients included in the study.
4.4. Proforma:
The proforma was filled with the details like name, age, sex, ward, clinical diagnosis,
risk factors, undergone any surgery and other parameters significant to the present study.
4.5. Sample collection:
After getting informed consent median cubital vein was selected for sample
collection, area is cleaned with surgical spirit and allowed to air dry, 5ml of blood is collected
separated as 3 parts 1ml for ESR in blood collection tube with EDTA, 2ml for Rheumatoid
factor , C-reactive protein, Anti-nuclear antibody examination and 2ml for HLA B27 PCR in
test tube with EDTA.
4.6.Sample storage:
2ml of whole Blood with EDTA stored at -20°C for HLAB27 detection.
4.7.Tests performed
The following tests were performed
1. Erythrocyte Sedimentation rate ,
2. Latex agglutination test for C- Reactive protein,
3. HLA B27 DNA PCR
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4.8. Erythrocyte sedimentation rate(ESR):
Blood samples for ESR were send to biochemistry department and results were
collected.
4.8.1.Principle
In the modified Westergren method for determining erythrocyte sedimentation rate
(ESR), anticoagulated blood is diluted with 0.85% saline and aspirated into a calibrated
tube. The cells are allowed to settle for a period of exactly one hour.
4.8.2. Reagents and Equipment
 Westergren pipet - must meet NCCLS' specifications
 Westergren pipet rack
 Timer
 0.85% NaCl
 Test tubes, 13x100 mm
 Pipets, 2.0 mL & 0.5 mL
Overall length: 300.5 + 0.5 mm
Internal diameter: 2.65 + 0.15 mm
External diameter: 5.5 + 0.5 mm
Uniformity of tube bore: + 0.05 mm
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4.8.3.Quality Control
Commercial quality control materials with established control limits were ran
periodically. The frequency is determined by each laboratory's workload. For instance, quality
control material may be run at the beginning of each eight-hour shift.
4.8.4. Specimen
Whole blood is the specimen of choice. The ESR should be set up within six hours
after collection.
4.8.5. Procedure:
1. Specimen preparation
a. Pipetted 0.5 mL of 0.85% NaCl in a labelled 13 x 100 mm test tube.
b. 2.0 mL of well-mixed whole blood was added to the test tube.
c. Test tube was mixed to obtain an even suspension.
2. Using a pipette , the Westergren pipet was filled upto the "0" mark (+ 1 mm) with the
diluted blood sample. outside of the pipet was wiped off  with gauze. If necessary,the
volume of blood adjusted the to the "0" mark. There was no bubbles in the blood.
3. Westergren pipet was placed in the pipet rack. Make sure the pipet fits snugly to
eliminate possible leakage and that the pipet is in a vertical position.
4. Timer set for one hour.
5. In exactly one hour, the distance in millimeters between the meniscus of the plasma and
the top of the sedimented erythrocyte column was recorded. Do not included the buffy coat in
the reading. The resulting distance was the erythrocyte sedimentation rate in mm/hr.
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4.8.6. Reference Interval
Adult Males: 0-10 mm/hr
Adult Females: 0-20 mm/hr
Children: 0-10 mm/hr
4.9. Serum CRP level detection by latex agglutination test:
All the 50 samples were tested for CRP detection by latex agglutination test with the
help CRP test kit of SPAN DIAGNOSTICS LTD, INDIA.
4.9.1. Principle:
Specially selected polystyrene latex particles are coated with monospecific goat anti
human CRP antibodies. When a serum positive for C - reactive protein is mixed with the latex
reagent, a positive result is indicated by a distinctly visible agglutinationof the latex particles in
the test circle of the slide used. In specimen negative for C –Reactive Protein, the latex remains
in a smooth suspension form in the test circle.
4.9.2. Materials provided:
C - reactive protein latex agglutination test kit contains the following items to
Perform the assay.
 Latex reagent for tests – Suspension of polystyrene latex particles, coated with
 Monospecific goat anti-human CRP antibodies.
 Positive Control serum – 0.5ml
 Negative Control serum – 0.5 ml
 Disposable slides with 8 test cells.
 Disposable mixing sticks.
 Disposable plastic droppers with a rubber teat.
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4.9.3. Storage
C - reactive protein latex agglutination kit was stored at 2-8 ˚C.
4.9.4. Test procedure:
4.9.4.1.Qualitative analysis:
 The latex reagent, controls and serum specimens were brought to room temperature.
 The antigen suspension was mixed thoroughly prior to use.
 One drop each of patient serum, positive and negative control sera were placed in
respective cells of the test plate.
 Then one drop each of CRP latex reagent was added to each of these sera.
 The sera and latex reagent were mixed with separate mixing sticks and the fluid
spread over the entire area of the particular cells.
 The test slide was tilted back and forth for two minutes so that the mixture rotates
slowly inside the cells .
 At the end of two minutes the results were read under bright light.
Interpretation of results:
 Strong Positive – Distinct coarse agglutination occurs within 0.5 minute.
 Weakly Positive – Fine agglutination usually taking full 2 minutes.
 Negative - No agglutination.
 Distinct agglutination indicates CRP content of more than 6 mg/litre in undiluted
serum specimen.
 Sera with positive results in the screening were tested in the titration
test.
4.9.4.2. Semi quantitative analysis:
0.9% saline solution was prepared. Then the specimen was diluted with salineuntil the last
dilution giving distinct agglutination.
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 Titre is the last dilution step giving visible agglutination. Read the titre in the last
dilution step with agglutination and multiply the titre with the conversion factor 6 to get
the results in mg/litre.
With the above standard guidelines, samples were tested and obtained resultswere documented.
4.10.Polymerase chain reaction
Real-time PCR Kit is an in vitro nucleic acid amplification kit for the detection of HLA-B27
Genotype [HLA-B 27:01 to 27:73] in Human blood samplesobtained from HELINI
BIOMOLECULES, Chennai.
It constitutes a ready to use system for the detection of HLA-B27 genotype using polymerase
chain reaction (PCR). It contains reagents and enzymes for the specific amplification of 150bp
region of the HLA-B27 region of human genome, and for the direct detection of the specific
amplicon in fluorescence channels Cycling Green. In addition, it contains an Internal control
amplification system to identify possible PCR inhibition. External positive control
(HLAB27Positive Template) is included
Dilution CRP (mg/litre non-diluted specimen)
1:2 12
1:4 24
1:8 48
1:16 96
1:32 192
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4.10.1. Storage
The content of the kit should be stored at –20°C, Storage at 2–8°C should not exceed a period
of 5 hours
4.10.2. Specificity
HLA-B27 primer and Probe have been designed for the specific and exclusive in
vitro detection of HLA-B27 genotypes. The Primer Probe can able to detect all the subtypes
ranging from B27:01 to B27:73. The target sequence is highly conserved and has previously
been shown to be a good genetic marker for the detection of HLA-B27 genotyping. The
Primers and probe sequences in this kit have 100% homology with a broad range of clinically
relevant reference sequences based on a comprehensive bioinformatics analysis
4.10.3. Dynamic range of test
Under optimal PCR conditions this kit has very high priming efficiencies of >95%
and can detect less than 20 copies of target template
4.10.4. Principle – Real time PCR
Polymerase chain reaction (PCR) is based on the amplification of specific regions
of the genome. In real-time PCR the amplified product is detected viafluorescent dyes. These
are usually linked to Oligonucleotideprobes that bind specifically to the amplified product.
Monitoring the fluorescence intensities during the PCR run (i.e., in real time)allows the
detection and quantitation of the accumulating productwithout running in agarose gel
electrophoresis following by gel documentation
4.10.5.Positive control
A positive result indicates that the primers and probes for detecting the target
pathogen gene worked properly in that particular experimental scenario. If a negative result is
obtained the test results are invalid and must be repeated. Care should be taken to ensure that
the positive control does not contaminate any other kitcomponent which would lead to false-
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positive results. This can beachieved by handling this component in a Post PCR environment.
Care should also be taken to avoid cross-contamination of other samples when adding the
positive control to the run. This can be avoided by sealing all other samples and negative
controls before pipetting the positive control into the positive control well.
4.10.6.Negative control
To confirm the absence of contamination, a negative control reaction should be
included every time the kit is used. For this reaction, the RNAse/DNAse free water should be
used instead of template. A negative result indicates that the reagents have not become
contaminated while setting up the run. If a positive result is obtained the results should be
ignored and the test samples repeated. Possible sources of contamination should first be
explored and removed
4.10.7.Internal Control template
When performing DNA extraction, it is often advantageous to have an exogenous
source of nucleic acid template that is spiked into the lysis buffer. This internal control nucleic
acid template is then co-purified with the sample DNA and can be detected as a positive
control for the extraction process. Successful co-purificationand real-time PCR for
the control template also indicates that PCR inhibitors are not present at a high concentration.
The primer and probe present at PCR limiting concentrations which allows multiplexing with
the target sequence primers. Amplification of the Internal control template does not interfere
with detection of the target gene even when present atlow copy number. The Internal control is
detected through the HEX channel and gives a CT value of 26 +/-3.
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Add 5μl of the internal control template to each sample. Do notadd directly to sample.
Add to sample/lysis buffer complex
4.10.8. Materials Required
 0.2 ml PCR tubes
 Micro Pipettes Variable Volume 0.5-10μl, 10-100μl, and 100-1000μl
 Sterile pipette tips with aerosol barrier 2-20μl, 10-100μl, and 100-1000μl
 Disposable powder-free gloves
 Vortex mixer and Water bath
 Centrifuge with rotor for 1.5 ml reaction tubes
 1.5ml centrifuge tubes
4.10.9.HLA-B27 PCR PROTOCOL
Preparation of reagents
1. Lysis buffer- ready to use –store at -20°C
2. Elution buffer- ready to use- store at -20°C
3. Proteinase K – ready to use- store at -20°C
4. AW1- wash buffer 1 (18ml) + Added 12ml of 100% ethanol – stored at Room temperature
5. AW2- wash buffer 2 (12ML) + Added 48ml of 100% ethanol – stored at Room
temperature
6. To PCR grade water added
*240µl to HLA B27 mix
*150µl to IC template vial
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*150µl to Positive control vial
Incubated in Room temperature for 15min, Vortexed for 5 seconds, Incubated in Room
Temperature for 15 min then Vortexed for 5 seconds, Centrifuged at 2000rpm for 10 seconds,
finally Stored at -20°C.
Sample:
Fresh whole blood added with EDTA ( 1mg/ml of blood) Or if stored at -20°C bring down to
room temperature
4.10.10.DNA extraction
1. Took 1.5 ml PCR tube, added 20µl of proteinase K then added 200µl of sample and
200µl of Lysis buffer and 5µl of IC
2. Vortexed and  incubated at 56°C in water bath for 15 min
3. Then added 100% ethanol 220µl then vortexed and brief centrifuge was done
4. Spin column was taken and transferred the specimen and centrifuged at 8000rpm for
1min
5. Changed the collection tube , Added 500µl of AW1and centrifuged at 10000rpm for
1min
6. Changed the collection tube , Added 500µl of AW2 and centrifuged at 10000rpm for
1min
7. Changed the collection tube , Added 500µl of AW2 and centrifuged at 10000rpm for
1min
8. Changed the collection tube , using Empty spin  centrifuge was done at 12000rpm for
2min
9.  Spin column was placed in 1.5ml PCR tube , then 100µl of elution buffer was   added,
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Incubate in Room Temperature for 2min ,centrifuge at 10000rpm for 1min
10. Discarded the spin column, filtrate was containing DNA
4.10.11.Reaction
Arrange PCR tube block as Negative Control, Sample 1,Sample 2,Sample 3,etc.. , Positive
Control, Components of detection mix were added as follows
*HLA-B27 mix 15µl in all wells
*Add 10µl of Negative Control, Sample, Positive Control in respective wells
4.10.12.Detection Protocol
Things to do before starting
Before each use, all reagents need to be thawed completely, mixed (by gentle
inverting several times), and centrifuged briefly. Make sure that Positive and Negative control
is included for every qPCR run. Make sure that internal control template is added during DNA
purification.
4.10.13.Detection Mix
Components Volume
Probe PCR Master Mix 8μl
Taq enzyme mix 2μl
HLA-B27 PP Mix 2.5μl
IC PP Mix 2.5μl
Purified DNA sample [100-250ng] 10μl
59
Total reaction volume 25μl
4.10.14.Negative Control setup
10μl of nuclease free water instead of Purified DNA sample was used as negative control.
4.10.15.Positive Control setup
10μl of Positive control template [QS1] provided in the kit was used.
4.10.15.Amplification Protocol
Step Time Temp
Taq enzyme activation 15min 95°C
40cycles Denaturation 20sec 95ºC
Annealing/Data collection* 20sec 55ºC
Extension 20sec 72ºC
HLA-B27 = FAM channel  ,Internal Control = HEX Channel
4.10.16.Interpretation of Results
Negative control
The Negative control reactions should not exhibit fluorescence growth curves
that cross the threshold line. If a false positive occurs with one or more of the NTC reactions,
sample contamination may have occurred. Invalidate the run and repeat the assay with stricter
adherence to the procedure guidelines.
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Positive Control
Positive control reactions should produce positive results before 30 cycles. If
expected positive reactivity is not achieved, invalidate the run and repeat the assay with stricter
adherence to the procedure guidelines.
Test Sample/Specimen - Positive
When all controls meet stated requirements, a test sample/specimen is considered
presumptive positive.
Test sample/Specimen - Negative
When all controls meet the stated requirements, sample is considered negative.
Sample Negative
control
Positive
control
Internal
Control
Interpretation
Positive Negative Positive Positive Detected
Negative Negative Positive Positive Not detected
Negative Negative Negative Negative Experiment Fail
Positive Positive Positive Positive Experiment Fail
4.10.17.Limitations
A false negative result may occur if inadequate numbers of cells are present in the sample due
to improper collection, transport or handling. A false negative result may occur if an excess of
DNA template is present in the reaction. If late CT or inhibition of the Internal control is noted
for a particular sample, purified DNA can be tested at 2 or more dilutions [e.g., 1:3 and 1:5) to
verify the results.
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5.RESULTS
5.1 Study Description:
The study was conducted at the Department of Microbiology, Tirunelveli Medical College, over
a period of one year from April 2016 to May 2017.A total of 100 blood samples,50 samples from
suspected Spondyloarthropathy subjects and 50 samples from normal individuals. These blood
samples were subjected to ESR, CRP by latex agglutination method, HLA B27 detection by
PCR. Results were analyzed between two groups.
5.2 Statistical analysis and Interpretation:
The Spondyloarthropathy (SpA) and normal individuals (Non Spondyloarthropathy
Patients- N S A) subjects were analyzed and interpreted according to the type of variables. The
continuous variables were described in terms, averages and interpreted by student independent
“t” tests. The category variables were described in terms of percentages and interpreted by χ2
(Chi-square) tests. The proportions were interpreted by “Z” tests. The level of statistical
significances were fixed as P- values less than or equal to 0.05 (P≤0.05).
5.3 Gender wise age distribution of Subjects:
The study subjects namely Spondyloarthropathy (SpA) and Non Spondyloarthropathy
(NSA) subjects had been described according to their demographic and clinical characteristics.
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Table 1: Gender wise age distribution of SpA subjects:
Age group
(years)
Male Female Total
Frequency % Frequency % Frequency %
<20 3 6.0 1 2.0 4 8.0
20-29 3 6.0 2 4.0 5 10.0
30-39 11 22.0 11 22.0 22 44.0
40-49 5 10.0 6 12.0 11 22.0
50-59 3 6.0 4 8.0 7 14.0
60+ 1 2.0 0 0.0 1 2.0
Total 26 52.0 24 48.0 50 100.0
Mean± SD 36.4 ± 11.5 38.5±9.5 37.4±10.6
Significance t=0.704, df=48, P>0.05 Range=62-14=48
The table-1 states that the gender wise age distribution of SpA subjects. In the age bracket of 30-
39 years, the both gender of the SpA subjects was 22% as maximum. The mean ages of males
and females were 36.4 ± 11.5 years and 38.5±9.5 years respectively. The difference of age
between the two genders was not statistically significant (P>0.05). The mean age of SpA subjects
was 37.4±10.6 with the range of 48 years.
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5.4. Analysis of Gender wise age distribution among  NSA subjects
Table 2: Gender wise age distribution of NSA subjects:
Age group
(years)
Male Female Total
Frequency % Frequency % Frequency %
<20 3 6.0 2 4.0 5 10.0
20-29 12 24.0 11 22.0 23 46.0
30-39 8 16.0 10 20.0 18 36.0
40-49 1 2.0 3 6.0 4 8.0
50-59 0 0.0 0 0.0 0 0.0
60+ 0 0.0 0 0.0 0 0.0
Total 24 48.0 26 52.0 50 100.0
Mean± SD 28.3±6.9 30.2±7.5 29.3±7.2
Significance t=0.932, df=48, P>0.05 Range=45-17=28
The gender wise age distribution of NSA subjects was shown in the above table-2. In
respect of males, in the age group 20-29 years 24% was the maximum and in respect of females
also 22% was the maximum. The mean ages of males and females were 28.3±6.9 years and
30.2±7.5 years respectively. The difference of mean age between the two genders was not
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statistically significant (P>0.05). The mean age of NSA subjects was 29.3±7.2 with the range of
28 years.
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5.5. Distribution of symptom duration in SpA group
Table-3: Symptom duration between genders of SpA subjects:
Symptom duration
(months)
Male Female Total
No % No % No %
<12 14 28.0 15 30.0 29 58.0
12-23 3 6.0 3 6.0 6 12.0
24-35 4 8.0 4 8.0 8 16.0
36+ 5 10.0 2 4.0 7 14.0
Total 26 52.0 24 48.0 50 100.0
Mean± SD 14.8 ±12.5 12.9±11.4 13.9±11.9
Significance t=0.569, df=48, P>0.05 Range=48-3=45
The symptom duration between the gender of SpA subjects was stated in the above table-5.In
both gender, the male was 28% and female was 30% with <12 months as maximum. The mean
durations of both gender were 14.8 ±12.5 and 12.9±11.4 months. The difference between them
was not statistically significant (P>0.05). The total mean duration of SpA group subjects was
13.9±11.9 months with range of 45 months.
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5.6. Analysis of  X- Ray evidence of SpA:
Table-5: HLAB27 positive and negative of SpA subjects Screened by X Ray
Gold
Screening
HLAB27
Positive Negative Total
X Ray
Positive 6 0 6
Negative 7 37 44
Total 13 37 50
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The prediction of positive and negative  among HLAB27 positive and negative of SpA
subjects were screened by X Ray. Xray shows evidences of SpA only in 6 patients among 13
HLA B27 positive patients, Sensitivity screened by X Ray=46.2%, Specificity screened by X
Ray = 100%.
Positive Negative
Total 6 44
HLAB27 13 37
X Ray 6 44
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5.7. Analysis of MRI evidence of SpA:
Table-6: HLAB27 positive and negative of SpA subjects Screened by MRI
Gold
Screening
HLAB27
Positive Negative Total
MRI
Positive 12 0 12
Negative 1 37 38
Total 13 37 50
The prediction of positive and negative among HLAB27 positive and negative of SpA
subjects were screened by MRI.MRI shows changes in 12 patients who were also positive for
HLA B27.Sensitivity screened by MRI=92%,Specificity screened by MRI = 100%.
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Positive Negative
Total 12 38
HLAB27 13 37
MRI 12 38
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5.8. Analysis of screening by ESR :
Table-4: HLAB27 positive and negative SpA subjects Screened by ESR
Gold
Screening
HLAB27
Positive Negative Total
ESR
Positive 8 0 8
Negative 5 37 42
Total 13 37 50
The prediction of positive and negative  among HLAB27 positive and negative of SPA
subjects were screened by ESR. ESR raised in only 8 patients among 13 HLA B27 positive
individuals.Sensitivity screened by ESR=61.5%,Specificity screened by ESR = 100%.
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Total 8 42
HLAB27 13 37
ESR 8 42
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5.9. Analysis of screening by CRP:
Table-7: HLAB27 positive and negative of SpA subjects Screened by CRP
Gold
Screening
HLAB27
Positive Negative Total
CRP
Positive 10 0 10
Negative 3 37 40
Total 13 37 50
The prediction of positive and negative among HLAB27 positive and negative of SpA
subjects were screened by CRP.CRP is positive in 10 patients among 13 HLAB27 positive
individuals. Sensitivity screened by CRP=76.9%, Specificity screened by CRP = 100%
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Positive Negative
Total 10 40
HLAB27 13 37
CRP 10 40
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5.10. Analysis of HLAB27 detection by PCR
Table -8: Interpretation of HLAB27 detection by PCR.
GROUP TOTAL POSITIVE NEGATIVE
SPA 50 13 26% 37 74%
HEALTHY
POPULATION
50 0 0% 50 100%
Among 50 suspected Spondyloarthropathy subjects HLAB27 was detected only in 13
patients(26%), 37 patients were negative (74%).so the association between SpA and HLAB27 is
26% in this study.
Among 50 healthy population no one was positive for HLA B27, so the prevalence of
HLAB27 in normal population in this study is 0%.
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5.11.Age wise Distribution of  HLAB27 positive subjects:
Table-9: Age wise HLAB27 positive of SpA subjects.
Age group (years)
HLAB27 positive
No %
<20 2 15.4
20-29 3 23.0
30-39 6 46.2
40-49 1 7.7
50-59 1 7.7
60+ 0 0.0
Total 13 100.0
Mean± SD 31.2±9.7
Sig t= 2.602, df=48, P<0.05
The table-9 compares the HLAB27 positive subjects of SpA according to their age. The
mean age of HLAB27 positive was 31.2±9.7 years. The difference of mean age was statistically
significant (P<0.05).
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5.12.Gender wise distribution of HLAB27 positive subjects:
Table-10: Genderwise HLAB27 positive and negative of SpA subjects
Gender
HLAB27 positive Results & Sig
No %
Male 7 53.8 χ2=0.024
df=1
P>0.05
Female 6 46.2
Total 13 100.0
The table-17 compares HLAB27 positive SpA subjects according to the genders. There
was no statistically significant association was found between the gender in respect of HLAB27
positive (P>0.05).
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5.13. Problem wise distribution:
Table-11: Problem wise HLAB27 positive and negative of SpA subjects.
Problems
HLAB27
positive
n=13
HLAB27
negative
n=37
“Z” Sig
Total n=50
No % No % No %
Jt involve 6 46.2 4 10.8 2.402 P<0.05 10 20.0
Ocular 2 15.4 2 5.4 0.936 P>0.05 4 8.0
RS 1 7.7 1 2.7 0.636 P>0.05 2 4.0
CVS 2 15.4 1 2.7 1.226 P>0.05 3 6.0
Skin 2 15.4 2 5.4 0.936 P>0.05 4 8.0
Renal 0 0.0 0 0.0 0.0 - 0 0.0
UTI 4 30.8 3 8.1 1.673 P>0.05 7 14.0
Endocrine 3 23.1 0 0.0 1.976 P<0.05 3 6.0
ESR 8 61.5 0 0.0 4.557 P<0.001 8 16.0
CPR 10 76.9 0 0.0 6.578 P<0.001 10 20.0
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The table-11 compares the incidences of problems among the HLAB27 positive and
negative of SpA subjects. The other joint involvement (46.2%) among the HLAB27 positive was
statistically significant with HLAB27 negative (P<0.05).
The ocular problems(15.4%) among the HLAB27 positive was not statistically significant with
HLAB27 negative (P>0.05).
The RS incidences (7.7%) among the HLAB27 positive was statistically not significant with
HLAB27 negative (P>0.05).
The CVS incidences (15.4%) among the HLAB27 positive was statistically not significant with
HLAB27 negative (P>0.05).
The skin problem (15.4%) among the HLAB27 positive was statistically not significant with
HLAB27 negative (P>0.05).
The chronic UTI incidences (30.8%) among the HLAB27 positive was statistically not
significant with HLAB27 negative (P>0.05).
The endocrine problem (23.1%) among the HLAB27 positive was statistically significant with
HLAB27 negative (P<0.05).
The ESR incidences (61.5%) among the HLAB27 positive was statistically significant with
HLAB27 negative (P<0.001).
The CPR incidences (76.9%) among the HLAB27 positive was statistically significant with
HLAB27 negative (P<0.001).
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5.14 Analysis of HLAB27 positivity in various problems
Table-12: HLA B27 association in various problem
Problems Total cases HLA B27 positive Percentage of HLAB27
association
Ocular 4 2 50%
RS 2 1 50%
CVS 3 2 66.6%
Skin 4 2 50%
Renal 0 0 0
UTI 7 4 57%
Endocrine 3 3 100%
In a total of4 individuals with ocular problem only 2 (50%) are positive for HLA B27.Out of 2
patient having upper lobe consolidation only one (50%) is positive for HLAB27. Out of 3 patients
having Cardiac problem only 2(66.6%) are positive with HLAB27. Out of 4 patients with skin
problems(psoriasis) only 2 were positive for HLAB27. In this study 7 SpA patients have chronic
urinary tract infection, out of this only 4(57%) were positive for HLAB27. In this study 3 patients
in SpA group having endocrine problems in that all are positive with HLAB27
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6. DISCUSSION
HLAB27 is an antigen expressed on the surface of all nucleated cells which is encoded
by B27 allele in the B locus of MHC present chromosome 6. The presence of this antigen in
some individuals predisposes to development of  Spondyloarthropathy(SpA) in any part of their
life.SpA constitutes a spectrum of diseases which includes Ankylosing spondylitis (AS),Reactive
arthritis (ReA), Psoriatic arthritis (PsA), Enteropathic arthritis, a subgroup of juvenile chronic
arthritis, and Undifferentiated Spondyloarthropathy (USpA). Prototype among all these is
Ankylosing spondylitis (AS) which is most commonly associated with HLAB27. The common
pathology of all these diseases is inflammation of sacroiliac joint thus the common symptom is
back pain which has some specific characters.
Diagnosis of  these diseases are delayed due to late appearance of features of SPA in
conventional radiography however MRI can detect the early changes of inflammatory arthritis
nowadays. Detection of HLA B27 antigen in peripheral blood in early stages of these diseases
will help to exclude other causes of inflammatory arthritis and those individuals are classified as
SpA and to start treatment early which includes physical exercise, NSAIDS, DMARDS, Anti-
tumour necrosis factor therapy. Early diagnosis of SPA is also important in screening of other
diseases like anterior uveitis, cardiac problems, pulmonary consolidation, renal diseases, etc, in
which HLA B27 will be a predisposing factor and it is particularly more helpful in diagnosis of
SpA in young individuals before the appearance of radiological changes. HLA B27 detection is
also useful for screening of relatives who are also positive for
HLA B27 and having increased risk to develop SpA
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6.1. Age – Sex wise distribution SpA:
The present study showed that the mean age of SpA subjects was 37.4±10.6.  Study
group contains a total of 50 individuals with symptoms of SpA, among them 26(52%) are male
and 24(48%) are female with male: female ratio of 1.08:1.
In a study conducted by Seager K et al stats that, Clinically SpA is more common in
males, with a reported male-to-female ratio of about 2 : 1 to 3 : 1. However, studies on the genetic
marker HLA-B27 suggest that, on the basis of radiographs of the SI joints, prevalence rates are
equal in both sexes (90).
6.2. Distribution of ocular problems:
In the study group 4 subjects (31%) were having ocular problems.In a total of4 subjects
with ocular problem only 2 (50%) are positive for HLA B27.
In a study of Linssen et al ,Approximately 1% of HLA-B27 positive individuals
develop acute anterior uveitis (AAU) in their life time(54).
In a study conducted by Rosenbaum JT et al, About 20–30% of patients with ankylosing
spondylitis or Reiter’s syndrome develop AAU (55).
6.3. Distribution of respiratory problems in study group
In this study group 2(4%) subjects were having consolidation. Out of 2 patients having
upper lobe consolidation among them only one (50%) is positive for HLAB27.
Study by Strobel et al stats that Lung involvement is a rare and late manifestation of AS.
It is characterized by slowly progressive fibrosis of the upper lobes of the lungs,
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appearing, on average, 2 decades after the onset of AS. Patients may complain of cough,
dyspnoea, and sometimes haemoptysis (82).
6.4. Distribution of CVS problems in study group
In the study group, 3 were having cardiac problems, out of these only 2(66.6%) are
positive with HLAB27.
In the study conducted by Granam DC et al stats that Aortic incompetence was seen
in 3.5% of patients and in 10% who had the disease for 15 years and after 30 years
respectively.Inflammation and dilation of the aorta are the main causes of aortic valve
incompetence. Cardiac conduction disturbances are seen with the passage of time, occurring in
2.7% of those with disease of 15 years’ duration and in 8.5% after 30 years (80).
6.5. Distribution of skin problem in study group
Out of 4(8%) subjects with skin problems(psoriasis) 2 (50%)were positive for
HLAB27. Among patients with psoriasis, 7% to 42% develop arthritis.
In a study of Gelfand JM et al,The prevalence of psoriatic arthritis ranged
from0.056% to 0.28% in a large population-based study in theUnited States. (96)
6.6. Distribution of Renal problems in study group
None of the patients in this study had renal problem.In this study 7(14%)SPA patients have
chronic urinary tract infection,out of this only 4(57%) were positive for HLAB27.
In a study conducted by LaiKN et al , IgA nephropathy has been reported in many
patients with AS. These patients often have an elevated immunoglobulin (Ig)A level (93%) and
renal impairment (27%) at presentation .(84)
In Vilar MJ et al study, Proteinuria and Microscopic haematuria may occur in up to
35% of patients with AS. But the significance of these findings in terms of subsequent
deterioration of renal function is unclear. (85)
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6.7. Distribution of Endocrine problem in study group
In this study  group 3(6%)subjects were having endocrine problems among them all
(100%) are positive for HLAB27.
In a study of  Hrda P et al A 4-fold increased frequency of HLA-B27 has been found
in patients with autoimmune thyroiditis when compared with controls . (118)
6.8. Other joint involvement
In this study 10 subjects were having other joint involvement that is 20% of subjects
were presented with other joint involvement predominantly ankle joint and knee joint.
In a study conducted by Khan MA et al, Hips and shoulders are the most frequently
involved extra-axial joints in AS, The knee joint may also be affected in AS, often as an
intermittent effusion. The temporomandibular joint is involved in about 10% of patients. (78)
6.9. Peripheralsmear study
In this study 4 subjects in the study group shows microcytic hypochromic anemia (8%), all of
them were positive for HLAB27.
A mild normochromic anemia may be present in 15% of patients (101).
In this study microcytic hypochromic anemia may be due to iron deficiency it is not due to SpA.
6.10. Analysis of  usage of X-Ray in diagnosis
In this study only 6(12%) subjects were showing radiological evidences in conventional
radiography that is Among 13 HLA B27 positive patients only 6 (46.5%) showed radiological
evidences in conventional radiography.
In a study of Aufdermaur M conventional radiography lacks sensitivity in early
diagnosis of  sacroiliitis because it only detects structural abnormalities that are the consequence
of inflammation.(99)
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6.11. Analysis of usage of MRI in diagnosis:
In this study 12 subjects that is 24% were showing changes suggestive of SPA in
MRI, Among 13 HLA B27 positive patients 12 (92%) showed changes suggestive of SPA in
MRI.
In a study conducted by Weber U et al., MRI sequences that are used in routine practice
to image the SI joint can detect sacroiliitis in 50% of patients with pre-radiographic SpA.(100)
In a study by Tyrrell PNM et al., CTand MRI in AS allow the accurate non invasive
diagnosis of complication (119).
A study of Rawhya R et al showed that MRI had the sensitivity  of 66.7% for
detecting sacroiliitis. Their utility also most apparent in patients with disease duration less than
2 years. Plain radiographs showed the least sensitivity of 20% in detecting sacroiliitis. MRI was
also very useful in the patients with USpA where the radiographs were universally negative.(120)
In a study by Shanmuganandan and colleagues reported that MRI had the maximum
sensitivity (78%) for detecting sacroiliitis. Their utility was most apparent in patients with
disease duration less than 2 years. They were also very useful in patients with USPA (121).
MRI is the preferred modality in patients with early SPA and in those with USPA for
earlydiagnosis and useful for early treatment, it can also distinguish between acute and chronic
changes. It is beneficial for classifying different forms of SPAs and monitoring disease
progression before, during, and after any drug treatment. MRI should therefore be used whenever
possible to evaluate sacroiliitis in SpA (119).
6.12. Analysis by ESR
In this study 8subjects were showing raised ESR,  among 13 HLA B27 positive only
8(61.5%) showed raised ESR.
In a study conducted by Khan MA et al., An elevated ESR is reported in up to 75%
of patients in SpA, but it may not correlate with clinical disease activity(101).
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6.13. Analysis by CRP
In this study 10 (20%) subjects were positive for CRP, among 13 HLA B27 positive
patients only 10 (79.6%) were positive for CRP.
In a study conducted by Khan MA et al., An elevated CRP is reported in up to 75%
of patients, but it may not correlate with clinical disease activity (101).
6.14. HLAB27 detection by PCR
In this study Among 50 suspected SpA subjects 13 were positive for HLAB27 antigen,
so the association of HLAB27 with SpA in this study is 26%.
In other study conducted by Reveille JD ,It has been estimated that this allele is
responsible for up to 28% of the aetiology of SpA.(52)
6.15. HLAB27 in young SpA:
In this study 2 subjects with HLAB27 positivity were less than 20 years, among them
one subject is positive only for HLA B27 not showing evidence in MRI. So, HLAB27
detection by PCR is useful in early diagnosis of SpA.
In a study conducted by Weber et al., Sensitivity of  HLA B27 detection and MRI were equal
after 20years of age because radiological changes will be present in late diagnosis of SpA. In
young patients with inflammatory chronic back pain, a positive HLA-B27 test increases the
likelihood of having AS later, particularly if imaging of  the SI joints does not provide conclusive
results(100).HLA-B27 positivity is a highly useful predictor of early sacroiliitis (119).
6.16. Prevalence in normal population
In this study prevalence of HLA B27 in normal population is 0%.
In a study of pitchappan et al ,in south India HLAB27 frequency ranges from 0-2.5%
in normal population(122).
In comparing with the frequency of HLA B27 in normal population ,it is higher in
SpA . So there is a strong association of HLA B27 with SpA. So HLA B27 detection is very
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useful in diagnosis of SpA in early stages especially in Juvenile SpA. MRI also showed early
inflammatory changes it is a useful non invasive method for diagnosis.
But in young patients HLA typing is very helpful to classify the patients as SpA before
the development of inflammatory changes to an extend that can be detected  by radiography.
It is also useful as a prognostic marker in the management of SpA , because its
presence indicates that patient may have other system involvement.
A positive HLA B27 antigen also helpful to exclude the other causes of inflammatory
arthritis, it limits the diagnosis as SpA.
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7.SUMMARY
 In the present study SpA is more common in the age group of 30-39 years, most
patients presented with the symptoms of SpA belong to these age group
 Present study showed that symptoms of SpA were more and severe in male gender than
females.
 12 % of study subjets were having other joint involvement commonly knee and ankle
joint pain.
 50% of the subjects with ocular problem were positive for HLA B27, 50% of the
subjects with respiratory problem were positive for HLA B27, 66.6% of the subjects
with cardiac problems were positive for HLA B27, 50% of the subjects with skin
problem were positive for HLA B27, 57% of the subjects with chronic UTI were
positive for HLA B27 , all subjects with endocrine problem were positive for HLA
B27.
 12% of study subjects showed changes of SpA in X-Ray, all are HLA B27 positive,  X-
Ray fails to detect 53% of HLA B27 positive cases, so its sensitivity in early detection
of  SpA is lower than HLA typing
 24% of study subjects showed evidence of SpA in MRI, all of them were positive for
HLAB27, MRI failed to detect one subject in early onset SpA, so sensitivity of MRI in
comparison with HLA typing was low.
 ESR was raised in 16% of subjects in study group, these all were HLA B27 positive. As
a nonspecific test it was not raised in 38% of HLA B27 positive subjects indicating that
they(38%) were not in active inflammatory stage of SpA.
 CRP is positive in 20% of subjects , all of them were HLAB27 positive, CRP is not
positive in 15% of HLA B27 positive subjects, it is also a non specific test.
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 26% of subjects in study group were HLA B27 positive. So prevalence of HLA B27 in
SpA in this region 26%.
 HLA B27 was positive in one young subject with SpA, all other investigations failed to
detect this subject
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8.CONCLUSION
 This study highlights the prevalence of HLA B27 antigen in Seronegative
Spondyloarthropathy patients, strength of association is more between
HLA B27 antigen and SpA.
 Also highlights the prevalence of HLA B27 in normal population
 HLA typing is helpful in early diagnosis of SpA before the development of
Radiological features which can be detected by conventional X-Ray,
Computed Tomography, MRI.
 Detection of HLA B27 is important for institution of early treatment and to
investigate for other manifestations of SpA.it is also useful in screening of
other family members for HLA B27.
 HLA typing is also important to exclude other causes of inflammatory
arthritis.
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31 Blood 262/16 48 F cooli 3months A A A A A A A A A A ye
s
N
eg
at
iv
e
N
eg
at
iv
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
32 Blood 51563 37 F house
wife 10 months P(Ankle joint) A A A P A A A A P ye
s
N
eg
at
iv
e
N
eg
at
iv
e
N
o
rm
al
6µ
g/
dl
Po
sit
iv
e
33 Blood 132/17 41 F cooli 8months A A A A A A P A A A ye
s
N
eg
at
iv
e
N
eg
at
iv
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
34 Blood 119/16 42 F cooli 6months A A A P A A A A A A ye
s
N
eg
at
iv
e
N
eg
at
iv
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
35 Blood 276/16 53 F cooli 3years A A P A A A A A A A ye
s
N
eg
at
iv
e
N
eg
at
iv
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
36 Blood 23/17 33 F house
wife 8 months A A A A A A A A P P y
es
N
eg
at
iv
e
N
eg
at
iv
e
60
m
m
12
µg
/d
l
Po
sit
iv
e
37 Blood 266/15 39 F house
wife 2years A A A A A A A A A A y
es
N
eg
at
iv
e
N
eg
at
iv
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
38 Blood 57/17 33 F cooli 3months P(knee joint) A A A A A A A A A ye
s
N
eg
at
iv
e
N
eg
at
iv
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
39 Blood 287/15 33 M shop
owner
5months A A A A A A A A A A ye
s
N
eg
at
iv
e
N
eg
at
iv
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
40 Blood 178/16 14 M student 5months A A A A A A A A A A ye
s
N
eg
at
iv
e
N
eg
at
iv
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
s. no
sp
ec
im
en
IP/OP
A
G
E
SE
X
o
cc
u
pa
tio
n
DURATION OF
SYMPTOM
Other joint
involvement
O
C
U
LA
R
PR
O
BL
EM
R
S
In
v
o
lv
em
en
t
C
V
S
In
v
o
lv
em
en
t
SK
IN
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o
bl
em
s
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R
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41 Blood 294/14 30 F teacher 1years A A A A A A P A P P ye
s
N
eg
at
iv
e
N
eg
at
iv
e
56
m
m
10
µg
/d
l
Po
sit
iv
e
42 Blood 342/17 42 F house
wife 6months A A A A A A A A A A y
es
N
eg
at
iv
e
N
eg
at
iv
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
43 Blood 93/17 42 F driver 2years A A A A A A A A A A ye
s
N
eg
at
iv
e
N
eg
at
iv
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
44 Blood 184/17 38 F cooli 5months A A A A A A A A A A ye
s
N
eg
at
iv
e
N
eg
at
iv
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
45 Blood 165/17 17 M mechani
c
4months A P A A A A A A A A ye
s
N
eg
at
iv
e
N
eg
at
iv
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
46 Blood 261/16 62 M cooli 6months A A A A P A P A A A ye
s
N
eg
at
iv
e
N
eg
at
iv
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
47 Blood Aug-17 38 F cooli 1years A A A A A A A A A A ye
s
N
eg
at
iv
e
N
eg
at
iv
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
48 Blood 32/17 42 M cooli 1years A A A A A A A A A A ye
s
N
eg
at
iv
e
N
eg
at
iv
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
49 Blood 147/16 33 M cooli 2years P(Ankle joint) A A A A A A
P 
(T
yp
e 
2
D
M
)
A P ye
s
N
eg
at
iv
e
N
eg
at
iv
e
48
m
m
8µ
g/
dl
Po
sit
iv
e
50 Blood 26/17 42 M cooli 4months A A A A A A A A A A ye
s
N
eg
at
iv
e
N
eg
at
iv
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
s. no
sp
ec
im
en
IP/OP
A
G
E
SE
X
o
cc
u
pa
tio
n
DURATION OF
SYMPTOM
Other joint
involvement
O
C
U
LA
R
PR
O
BL
EM
R
S
In
v
o
lv
em
en
t
C
V
S
In
v
o
lv
em
en
t
SK
IN
Pr
o
bl
em
s
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R
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A
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u
r
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7
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R
51 Blood 17 F cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
52 Blood 43 M driver NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
53 Blood 32 F tailor NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
54 Blood 35 F cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
55 Blood 18 M cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
56 Blood 22 F cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
57 Blood 29 M cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
58 Blood 36 F cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
59 Blood 20 M shop
owner
NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
60 Blood 19 F student NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
s. no
sp
ec
im
en
IP/OP
A
G
E
SE
X
o
cc
u
pa
tio
n
DURATION OF
SYMPTOM
Other joint
involvement
O
C
U
LA
R
PR
O
BL
EM
R
S
In
v
o
lv
em
en
t
C
V
S
In
v
o
lv
em
en
t
SK
IN
Pr
o
bl
em
s
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n
ic
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e
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en
t
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O
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X
 
R
A
Y
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O
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A
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M
R
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v
ed
w
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D
s
R
A
FA
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TO
R
A
N
A
ES
R
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1h
o
u
r
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P
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B2
7
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R
61 Blood 21 M cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
62 Blood 29 F cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
63 Blood 25 M cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
64 Blood 40 F cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
65 Blood 39 M cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
66 Blood 38 F cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
67 Blood 35 M cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
68 Blood 41 F cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
69 Blood 34 M cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
70 Blood 26 F house
wife NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
s. no
sp
ec
im
en
IP/OP
A
G
E
SE
X
o
cc
u
pa
tio
n
DURATION OF
SYMPTOM
Other joint
involvement
O
C
U
LA
R
PR
O
BL
EM
R
S
In
v
o
lv
em
en
t
C
V
S
In
v
o
lv
em
en
t
SK
IN
Pr
o
bl
em
s
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ch
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n
ic
 
U
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in
e
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R
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Y
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O
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M
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w
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A
D
s
R
A
FA
C
TO
R
A
N
A
ES
R
 
in
1h
o
u
r
C
R
P
H
LA
 
B2
7
PC
R
71 Blood 19 M nurse NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
72 Blood 36 F cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
73 Blood 33 M cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
74 Blood 38 F cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
75 Blood 26 M cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
76 Blood 45 F cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
77 Blood 22 M cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
78 Blood 25 F driver NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
79 Blood 36 M cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
80 Blood 31 F cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
s. no
sp
ec
im
en
IP/OP
A
G
E
SE
X
o
cc
u
pa
tio
n
DURATION OF
SYMPTOM
Other joint
involvement
O
C
U
LA
R
PR
O
BL
EM
R
S
In
v
o
lv
em
en
t
C
V
S
In
v
o
lv
em
en
t
SK
IN
Pr
o
bl
em
s
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a
l
ch
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n
ic
 
U
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in
e
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en
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O
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X
 
R
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Y
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O
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M
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v
ed
w
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N
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A
D
s
R
A
FA
C
TO
R
A
N
A
ES
R
 
in
1h
o
u
r
C
R
P
H
LA
 
B2
7
PC
R
81 Blood 26 M house
wife NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
82 Blood 25 F cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
83 Blood 28 M cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
84 Blood 29 F cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
85 Blood 31 M house
wife NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
86 Blood 22 F house
wife NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
87 Blood 26 M cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
88 Blood 25 F shop
owner
NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
89 Blood 28 M student NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
90 Blood 24 F teacher NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
s. no
sp
ec
im
en
IP/OP
A
G
E
SE
X
o
cc
u
pa
tio
n
DURATION OF
SYMPTOM
Other joint
involvement
O
C
U
LA
R
PR
O
BL
EM
R
S
In
v
o
lv
em
en
t
C
V
S
In
v
o
lv
em
en
t
SK
IN
Pr
o
bl
em
s
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ic
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e
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A
 
IN
X
 
R
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N
SI
A
D
s
R
A
FA
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TO
R
A
N
A
ES
R
 
in
1h
o
u
r
C
R
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H
LA
 
B2
7
PC
R
91 Blood 18 M house
wife NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
92 Blood 27 F driver NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
93 Blood 24 M cooli NIL A A A A A A A
p(t
Y
PE
 2
D
M
)
A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
94 Blood 20 F mechani
c
NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
95 Blood 29 M cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
96 Blood 32 F cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
97 Blood 35 M cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
98 Blood 33 F cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
99 Blood 34 M cooli NIL A A A A A A A A A A
N
o
t g
iv
en
N
o
t d
o
n
e
N
o
t d
o
n
e
N
o
rm
al
N
eg
at
iv
e
N
eg
at
iv
e
100 Blood 38 F cooli NIL A A A A A A
s. no
sp
ec
im
en
IP/OP
A
G
E
SE
X
o
cc
u
pa
tio
n
DURATION OF
SYMPTOM
Other joint
involvement
O
C
U
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R
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R
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V
S
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t
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PROFORMA
Name :
Age&sex :
Address :
Occupation :
History:
1 .Back pain/Buttock pain - yes/no
Duration : Type of pain:
Aggravating/Relieving factor:
Early morning stiffness : yes/no
If yes improved by walking or exercise:
2. H/O Any other joint pain
3. Any other associated illness
4.Family H/O Sacroiliitis or HLA B27 positivity
GENERAL EXAMINATION
Anemia-
Jaundice-
Clubbing-
Deformity-
Respiratory system-
Cardiovascular system-
INVESTIGATIONS
Hb% : Imaging :
RA: ESR :
ANA: CRP :
HLA B27 PCR:
